Cancer Center Fact Sheets

The American Cancer Society and its sister advocacy organization, the American Cancer Society Cancer Action Network (ACS CAN), consider securing sustained federal investment in cancer research and programs a high priority. Through the One Voice Against Cancer (OVAC) coalition and other efforts, ACS CAN collaborates with leaders across the cancer community in developing a sophisticated and comprehensive strategy to tell the story of the value of cancer research.

As a central part of that effort, ACS CAN partnered with the Association of American Cancer Institutes (AACI) in reaching out to all center directors and staff to develop one-page fact sheets describing activities at each cancer center. The fact sheets included in this directory are the initial results of that effort.

As this project continues, we hope to add to the list of participating centers in this directory so we have a complete set of fact sheets covering every cancer center in the nation. These will be updated regularly to reflect new funding levels and research/activities as they emerge.

ACS CAN and AACI are very grateful to the centers who participated in this first phase of the project. If you have questions about this project, please contact ACS CAN staff:

Rebecca Kirch
Associate Director, Policy
Ph. 202-661-5725
Rebecca.Kirch@Cancer.org

Kristi Martin
Associate Policy Analyst
Ph. 202-661-5700
Kristi.Martin@Cancer.org
ACS CAN/AACI Cancer Center Fact Sheets
Table of Contents

Alabama
  • Comprehensive Cancer Center, University of Alabama-Birmingham

Arizona
  • Arizona Cancer Center, University of Arizona

Arkansas
  • Arkansas Cancer Research Center

California
  • The Burnham Institute for Medical Research
  • Beckman Research Institute, City of Hope National Medical Center
  • Loma Linda University Cancer Institute
  • Salk Institute for Biological Studies
  • Stanford Cancer Center, Stanford University School of Medicine
  • University of California, Davis Cancer Center
  • Chao Family Comprehensive Cancer Center, University of California, Irvine
  • Jonsson Comprehensive Cancer Center, University of California, Los Angeles
  • Moores Cancer Center, University of California, San Diego
  • Comprehensive Cancer Center, University of California, San Francisco
  • Norris Comprehensive Cancer Center, University of Southern California
  • John Wayne Cancer Institute

Colorado
  • University of Colorado Cancer Center

Connecticut
  • Carole and Ray Neag Comprehensive Cancer Center
  • Yale Cancer Center

District of Columbia
  • Lombardi Comprehensive Cancer Center, Georgetown University
  • George Washington University Cancer Institute
  • Howard University Cancer Center

Florida
  • H. Lee Moffitt Cancer Center and Research Institute, University of South Florida
  • University of Florida Shands Cancer Center
  • University of Miami Sylvester Comprehensive Cancer Center

Georgia
  • Winship Cancer Institute, Emory University
  • Medical College of Georgia Cancer Center

Hawaii
  • Cancer Research Center of Hawaii
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
- University of Chicago Cancer Research Center
- University of Illinois Cancer Center, University of Illinois at Chicago
- Cardinal Bernardin Cancer Center
- SimmonsCooper Cancer Institute, Southern Illinois University
Indiana
- Indiana University Melvin and Bren Simon Cancer Center
- Purdue University Cancer Center
Iowa
- Holden Comprehensive Cancer Center, University of Iowa
Kansas
- University of Kansas Cancer Center
Kentucky
- James Graham Brown Cancer Center, University of Louisville
- Lucille P. Markey Cancer Center, University of Kentucky
Louisiana
- Louisiana Cancer Research Consortium in New Orleans
Maine
- The Jackson Laboratory
Maryland
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
- University of Maryland Greenebaum Cancer Center, University of Maryland at Baltimore
Massachusetts
- Dana-Farber/Harvard Cancer Center
- Boston University Cancer Research Center
- Center for Cancer Research, Massachusetts Institute for Technology
- Tufts Medical Center Cancer Center
Michigan
- Barbara Ann Karmanos Cancer Institute, Wayne State University
- University of Michigan Comprehensive Cancer Center
- Van Andel Institute
Minnesota
- Mayo Clinic Cancer Center
- University of Minnesota Cancer Center
Missouri
- Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine
Nebraska
- University of Nebraska Medical Center, Eppley Cancer Center
Nevada
- Nevada Cancer Institute
New Hampshire
- Norris Cotton Cancer Center, Dartmouth College/Dartmouth-Hitchcock Medical Center

New Jersey
- The Cancer Institute of New Jersey, Robert Wood Johnson Medical School

New Mexico
- University of New Mexico Cancer Center

New York
- Albert Einstein Cancer Center, Yeshiva University
- Cold Spring Harbor Laboratory
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center and New York-Presbyterian Hospital
- James P. Wilmot Cancer Center, University of Rochester Medical Center
- Memorial Sloan-Kettering Cancer Center
- New York University Cancer Institute
- Roswell Park Cancer Institute, State University of New York
- Stony Brook University Cancer Center, State University of New York Stony Brook

North Carolina
- Duke Comprehensive Cancer Center, Duke University
- Lineberger Comprehensive Cancer Center, University of North Carolina
- Comprehensive Cancer Center of Wake Forest University

Ohio
- Case Comprehensive Cancer Center, Case Western Reserve University
- Cleveland Clinic Taussig Cancer Center
- The Ohio State Comprehensive Cancer Center, The Ohio State University
- UC Barrett Cancer Center at University Hospital, University of Cincinnati

Oregon
- Oregon Health Science University Cancer Institute

Pennsylvania
- Abramson Cancer Center, University of Pennsylvania
- Fox Chase Cancer Center
- Kimmel Cancer Center, Thomas Jefferson University
- Penn State Cancer Institute, Penn State University
- University of Pittsburgh Cancer Institute
- The Wistar Institute

South Carolina
- Hollings Cancer Center, Medical University of South Carolina

Tennessee
- St. Jude’s Children’s Research Hospital
- Vanderbilt-Ingram Cancer Center, Vanderbilt University
Texas
- The University of Texas M.D. Anderson Cancer Center
- Harold C. Simmons Comprehensive Cancer Center
- The Dan L Duncan Cancer Center, Baylor College of Medicine
- San Antonio Cancer Institute
- University of Texas Medical Branch Comprehensive Cancer Center

Utah
- Huntsman Cancer Institute

Vermont
- Vermont Cancer Center, University of Vermont

Virginia
- Massey Cancer Center, Virginia Commonwealth University
- University of Virginia Cancer Center

Washington
- Fred Hutchinson Cancer Research Center

West Virginia
- Mary Babb Randolph Cancer Center, West Virginia University

Wisconsin
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
- Medical College of Wisconsin Cancer Center
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The University of Alabama-Birmingham (UAB) Comprehensive Cancer Center received $33.3 million in total funding from the NCI for FY 2007, and has been an NCI designated Cancer Center since 1973.

As part of an elite group of NCI-designated Cancer Centers, the mission of the University of Alabama-Birmingham Comprehensive Cancer Center is to provide the most up-to-date and effective care to cancer patients, to advance the nation's scientific understanding of cancer, and to translate this new knowledge into improved diagnosis, treatment, and prevention.

- Named one of the first comprehensive cancer centers by NCI in 1973
- UAB is one of only 39 NCI-designated comprehensive cancer centers in the nation
- UAB is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News and World Report as one of the top 25 cancer hospitals in the United States in 2007
- UAB has three SPOREs: breast cancer, brain cancer, and pancreatic cancer
- An established leader in the field of antiviral chemotherapy
- The cancer-causing gene, GKLF, was discovered at UAB
- More than 500 faculty and staff members
- Receives more than $100 million in research support annually and is able to offer patients innovative cancer treatments and technology often unavailable elsewhere
- More than 175,000 square feet of space in eight buildings is dedicated to cancer research, including the new North Pavilion of University Hospital, where the administration is housed
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Arizona Cancer Center received $33.7 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1978.

As part of an elite group of NCI-designated cancer centers, the Arizona Cancer Center mission is challenging yet simple: “We exist to prevent and cure cancer.” Arizona Cancer Center accomplishes this goal through leading-edge care and treatment for those who have been diagnosed with cancer, through research into new techniques for prevention and cure, and through educational outreach programs that help millions reduce their risk for developing cancer.

- Arizona Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only such facility in the state of Arizona
- Arizona Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by *US News & World Report* as one of the top 50 cancer hospitals in the United States in 2007
- More than 270 physicians and scientists
- Has six major program project grants and is one of four cancer centers in the nation to have an NCI SPORE grant for gastrointestinal cancers
- Site of Arizona’s first bone marrow transplant program
- Provides a direct link between the latest research discoveries and patient care and has created more than 14 cancer-fighting drugs
- Developed and tested new drugs with significant impact on the treatment of patients with leukemia, colon cancer, ovarian cancer, and breast cancer
- Offers support groups, community-based services, and other supportive care services for patients, their families and caregivers
- Home to one of the nation’s leading cancer prevention research programs, developing treatments to prevent cancer incidence and recurrence in breast, colon, lung, prostate, and skin cancer, as well as tobacco cessation programs

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The Arkansas Cancer Research Center received $7.5 million in total funding from NCI in FY 2005.

The Arkansas Cancer Research Center (ACRC) strives to search for a cure for cancer, care for those with cancer, and teach others to search and care. These goals are accomplished at the ACRC through innovative clinical programs, public and professional education, community outreach, and research driven cancer care.

- The ACRC is the official cancer institute for the state of Arkansas and serves as the cornerstone of cancer-related activity for the state
- About 115,000 patient visits per year
- ACRC is a center of excellence at the University of Arkansas for Medical Sciences that includes 15 specialty clinics and seven support clinics
- The ACRC has 150 highly skilled faculty members involved in cancer-related activities
- Patients represent all 50 states and 44 countries
- The ACRC leads or participates in 167 clinical trials

- Cancer control activities include a mobile mammography unit, free cancer screenings and statewide efforts to reduce cancer disparities
- Current ACRC research programs include: multiple myeloma and bone, cell differentiation and signaling, molecular signatures and cancer therapeutics, and aging and cancer
- International recognition in myeloma research and treatment - more than 6,200 stem cell transplants have been performed to date
- ACRC hosts seminars, tours of the cancer center, and cancer programs and fellowships to educate about the disease and current research

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Cancer research at the Burnham Institute for Medical Research is a multi-disciplinary effort mobilizing more than 400 individuals working in a highly collaborative and interactive environment. Burnham’s scientists blend the most advanced technologies and expertise into their studies. Burnham’s cancer researchers promote an increasing emphasis on moving their basic scientific discoveries several steps closer to the clinic, thus making a substantial and steady mark on the prevention, diagnosis, and treatment of cancer.

- Burnham Institute is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Burnham Institute is a basic laboratory center, and does not provide clinical services to patients
- **San Diego Center for Chemical Genomics**, one of 9 centers funded as part of the Molecular Libraries Screening Centers Network Initiative (NIH Roadmap)
- A drug discovery program focused on apoptosis-based drug discovery, one of 8 awarded nationwide (funded by NCI)
- One of 6 NCI-funded centers defining molecular signatures of prostate cancer, aimed at developing more precise diagnostics (in collaboration with UC Irvine)
- One of 4 NCI-funded national centers of nanotechnology excellence (CCNE) (in collaboration with UC San Diego)
- Development of a Retinoid X (vitamin A based) compound that is FDA-approved for cutaneous T-cell lymphoma and in Phase II clinical trials for non-small cell lung cancer
- Discovery of the first DNA-based drug to complete Phase III randomized clinical trials for Chronic Lymphocytic Leukemia
- A synthetic analog known as Apo-Gossypol, which acts against Bcl-2 anti-apoptotic proteins, is under development by NCI’s RAID program for a variety of malignancies

*June 2008*
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Beckman Research Institute received $19.9 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1998.

As part of an elite group of NCI-designated Cancer Centers, the mission of the City of Hope is to be an innovative biomedical research, treatment and educational institution, dedicated to the prevention and cure of cancer and other life-threatening diseases, guided by a compassionate patient-centered philosophy, and supported by a national foundation of humanitarian philanthropy.

- City of Hope is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- City of Hope is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- City of Hope has a SPORE for lymphoma
- City of Hope is a founding member of the National Comprehensive Cancer Network, an alliance of the top cancer centers that defines and sets national standards for cancer care
- Employs more than 3,300 people
- Twenty percent of funding for the Institute comes from private donations from over 290,000 donors and volunteers
- Annually serves close to 20,000 people from 48 states, with more than 109,000 outpatient visits
- One of the first medical institutions to conduct bone marrow transplantation
- Using NIH funding, City of Hope has launched bone marrow transplant (BMT) studies and trials demonstrating the efficacy of “mini BMT,” lowering doses of chemotherapy in order to suppress the immune system so new grafts can take hold
- Conducts more than 300 clinical trials, with 1,100 patients participating in 2006
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The John Wayne Cancer Institute received $10 million in total funding from NCI in FY 2006.

John Wayne Cancer Institute at Saint John’s Health Center is a cancer research institute dedicated to the understanding and curing of cancer in order to eliminate patient suffering worldwide. Our mission is accomplished through innovative clinical and laboratory research and the education of the next generation of surgical oncologists and scientists.

- John Wayne Cancer Institute is one of the largest melanoma centers in the U.S. and remains at the forefront of melanoma clinical care and research
- The John Wayne Cancer Institute Breast Center at Saint John’s Health Center was named by Self Magazine as one of “America’s 10 Best Breast Cancer Centers”
- Surgical Oncology Fellowship Program is one of only 16 training programs in the U.S. approved by the Society of Surgical Oncology
- Researchers and physicians developed and adapted the Sentinel Node Technique, which has become the standard of care for melanoma and breast cancer
- One of the largest specimen repositories for cancer research in the world, with more than 1 million specimens linked to clinical data on disease stage, treatment, and outcome
- Scientists developed a blood test that can detect one tumor cell in 50 million blood cells, which may help locate and treat cancer at the earliest possible opportunity
- Offers prostatectomy patients a high-tech, minimally-invasive surgical approach through the use of the da Vinci Surgical System
- Houses one of the nation’s first Positive Appearance Centers – a boutique where patients can choose from a variety of wigs, hats, bras, camisoles, and prostheses
- Last year, cancer patients from 36 countries and from nearly every state traveled to the Institute

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The Loma Linda University Cancer Institute received $3 million in total funding from NCI in FY 2005.

Loma Linda University (LLU) Cancer Institute was established in 1991, in response to the growing need for a cancer center in southern California’s inland area that would be a leader in cancer prevention, early detection, treatment, research, and education.

- Currently, the LLU Cancer Institute is conducting more than 90 clinical trials
- In 2005, 2,044 cancer patients were diagnosed at LLU Cancer Institute and 15,853 patients were treated
- In 2005, 200 patients participated in clinical trials
- 22 staff members in the cancer institute that lend core support to the network of clinical cancer departments in the faculty medical office, the inpatient unit and the breast health center.
- LLU Center for Health Disparities and Molecular Medicine (CHDMM) is a National Center on Minority Health and Health Disparities (NCMHD) Research Center of Excellence, funded by awards from the NCMHD and NIGMS, NIH. The CHDMM team includes 17 leading faculty members engaged in the education, research and community outreach components of the center.
- LLU Cancer Institute’s Patient Resource Center provides education and support for cancer patients, their families, and health care professionals.

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Salk Institute received $7.2 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1973.

The NCI-designated Salk Institute Cancer Center is an integral part of the Salk Institute for Biological Studies. The Salk Institute explores questions about the basic principles of life, focusing on molecular genetics, the neurosciences, and plant biology. Although the Salk Institute does not provide patient care, it does focus on basic research that leads to innovative discoveries with potential application for patient treatment.

- Salk Institute is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Salk Institute is a basic biological research center, and does not provide clinical services to patients
- The Cancer Center was established at the Salk Institute in 1970
- The Salk Institute conducts its biomedical research in 21 laboratories
- Although not a degree-granting institution, the Salk Institute operates graduate programs in collaboration with University of California, San Diego and trains postdoctoral scientists. Since its inception the Salk has trained more than 2,300 scientists, including five Nobel laureates
- Research at the Salk Cancer Center is divided into three areas: molecular biology and genetics, growth control, and cell and developmental biology
- The Institute employs a faculty of 62 in addition to a scientific staff of 870, including trainees and students
- The Institute sponsors scientific seminars and symposia, including international scientific meetings
- The Institute supports a number of programs highlighting the value and rewards of science, including educational activities in middle and high schools

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Stanford Cancer Center (SCC) received $49.5 million in total funding from NCI in FY 2007.

The Stanford Cancer Center (SCC) is dedicated to unraveling cancer’s secrets and to transforming the latest detection, diagnosis, treatment and prevention discoveries into the most advanced patient care available. The SCC is committed to giving patients every clinical and technological advantage in the prevention and treatment of cancer.

- Ranked by US News & World Report as one of the top 15 cancer hospitals in the United States in 2007
- Medical teams of the SCC are engaged in more than 320 clinical trials and lead 124 clinical trials
- More than 290 researchers and clinicians
- Stanford scientists were the first to discover and isolate human leukemia and human breast cancer stem cells. Their efforts are now close to isolating stem cells for brain cancer, ovarian cancer, melanoma, and bladder cancer
- Treats 2,300 patients annually from 35 states and 19 countries
- Approximately 90,000 patient visits each year
- The SCC, in collaboration with the Northern California Cancer Center, has a range of community outreach programs designed to prevent cancer and improve the quality of life and outcome for those living with cancer throughout the Greater Bay Area
- Employs more than 390 people

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, the mission of the UC Davis Cancer Center is to provide premier multidisciplinary cancer care for Northern California cancer patients.

- UC Davis is the only NCI-designated Cancer Center serving California’s Central Valley and inland Northern California, a region of 6 million people
- UC Davis is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- More than 9,000 patients served annually from California and the surrounding states
- Developed a breast CT scan that may help to detect breast cancer earlier
- Home to the region’s largest and most experienced pediatric cancer treatment program and only pediatric bone marrow transplant program
- 29 scientists work on hundreds of research projects on three campuses
- First major cancer center to forge a formal research partnership with a national laboratory, Lawrence Livermore National Laboratory, to harness defense technologies in the fight against cancer
- Headquarters a $5.5 million NCI-funded project to eliminate cancer disparities in Asian-Americans nationwide
- Provides millions in uncompensated care each year for patients with limited or no health insurance
- Developed investigational new agents for leukemia, prostate, and neurologic cancers
- 150 adult clinical trials and 50 pediatric clinical trials at any given time

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Chao Family Comprehensive Cancer Center received $16.4 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1994

As part of an elite group of NCI-designated Cancer Centers, the mission of Chao Family Comprehensive Cancer Center at the University of California, Irvine, is to provide a receptive and familial atmosphere during one of the most difficult times of patients’ lives, when they have to bear the burden of those three words: “You have cancer.”

- The Chao Family Comprehensive Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only such facility in Orange County
- The Chao Family Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by U.S. News & World Report as one of the top 50 cancer hospitals in the United States in 2006
- The Center’s total membership includes 232 faculty and other academic staff from 10 schools
- The Center’s collaborations include 7 clinical, basic and population based research programs and 12 Shared Resource Facilities
- The Center is active in enhancing community outreach programs with target audiences for: African American men, Seniors, Women, Chinese Americans, and African American and Hispanic/Latina women
- The Chao Family Comprehensive Cancer Center has served over 4662 ambulatory cancer patients during FY 06-07
- The Center has participated in 242 trials since January 1, 2007
- NCI selected this center to develop and manage the largest database ever created on the genetic links in human cancer and to serve as California’s only research center in its nationwide Cancer Genetics Network
- The Center has an international reputation for its work with cancer

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, is to remain dedicated to innovation and excellence through interdisciplinary research and training and to serve as a community resource to sponsor and conduct informational and educational activities, providing a resource to both health care professionals and the public.

- The UCLA Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- The UCLA Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by *US News & World Report* as one of the top 10 cancer hospitals in the United States in 2007
- The UCLA Cancer Center has a SPORE in prostate cancer and lung cancer
- More than 20,000 patient visits per year
- Employs more than 230 physicians and scientists
- Named a LIVESTRONG Survivorship Center of Excellence by the Lance Armstrong Foundation
- One of three sites nationwide to conduct the first human tests on Gleevec
- Discoveries were made regarding an aggressive form of breast cancer which led to the development of Herceptin
- Developed the first animal model for prostate cancer
- The Jonsson Cancer Center conducts about 200 clinical trials annually

June 2008
Moores Cancer Center received $34.4 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1978.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Moores Cancer Center at the University of California, San Diego, is to conduct world-class, collaborative medical research to cure human disease, improve quality of life, and thus create a legacy for their employees, partners, donors, and community.

- The UCSD Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- The UCSD Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2007
- More than 78,800 outpatient visits are projected for 2007
- Selected as one of eight NCI-funded Centers of Cancer Nanotechnology Excellence
- Serves as the lead center for a national NCI-funded consortium to develop new therapies for CLL
- At any given time, the Center offers over 150 clinical trials
- Carries out research through seven programs: Cancer Biology, Cancer Genetics, Cancer Prevention & Control, Cancer Symptom Control, Hematologic Malignancies, Reducing Cancer Disparities, and Tumor Growth, Invasion and Metastasis
- Developed the first Smokers’ Helpline – a free, telephone-based smoking cessation service in 1990 – that has since grown to become a statewide service that has assisted more than 417,000 callers to quit
- Participates in six national cooperative groups for clinical trials
- At any given time, the Center offers over 150 clinical trials
- More than 330 faculty members of the Cancer Center, drawn from throughout the UCSD campus and San Diego

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The University of California, San Francisco (UCSF) Comprehensive Cancer Center received $69.2 million in total funding from the NCI in FY 2007, and has been an NCI-designated Cancer Center since 1999.

As part of an elite group of NCI-designated Cancer Centers, the overarching goal of the Comprehensive Cancer Center at the University of California, San Francisco, is to shepherd new approaches to cancer prevention, detection, and treatment into clinical and population settings, where they can be tested and evaluated.

- UCSF Cancer Center is one of only 39 NCI-designated comprehensive cancer centers in the nation
- UCSF Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 15 cancer hospitals in the United States in 2007
- The annual funding base to UCSF from NCI and other NIH sources totals $154 million
- Employs 430 physicians and scientists
- UCSF has three SPOREs: breast cancer, prostate cancer, and brain cancer
- Affiliated with Lawrence Berkeley National Laboratory, encompassing mutual interests in cancer research and technological discovery
- UCSF is an educational and outreach center, attracting health care professionals and cancer researchers
- UCSF is part of a collaboration to increase the number of minority students engaged in cancer research

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Norris Comprehensive Cancer Center at the University of Southern California is to maintain and build upon its status as a major regional and national resource for cancer research, treatment, prevention and education.

- The USC/Norris Comprehensive Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and was one of the first eight in the country to receive that designation
- The USC/Norris Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Served 3,833 new patients in 2005
- Cancer Center members currently hold research grants totaling more than $143 million
- Home to almost 200 researchers and scientists, conducting both thematic and translational research
- At any time more than 300 clinical trials may be taking place
- One of four institutions nationwide selected by the NCI to conduct the five-year, $54 million Transdisciplinary Research on Energetics and Cancer (TREC) initiative, which will unite researchers who focus on diet, weight and physical activity and their effects on cancer
- The USC/Norris Comprehensive Cancer Center, in collaboration with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, has been funded to establish a Cancer Genome Characterization Center (CGCC) as part of The Cancer Genome Atlas (TCGA) Pilot Project. Sponsored by the National Institutes of Health
- Slated to open in 2007, the Harlyne J. Norris Cancer Research Tower will be devoted to basic research

June 2008
COLORADO

UNIVERSITY OF COLORADO CANCER CENTER

Aurora, Colorado (7th Congressional District)
HTTP://WWW.UCCC.INFO

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The University of Colorado Comprehensive Cancer Center (UCCC) received $30.7 million in total funding from the NCI for FY 2007 and has been an NCI-designated Cancer Center since 1987.

As part of an elite group of NCI-designated Cancer Centers, the mission of the University of Colorado Comprehensive Cancer Center (UCCC) is to contribute to the elimination of cancer as a health problem through coordinated basic research, clinical, prevention and control, and educational activities; and provide the citizens of the State of Colorado and the Rocky Mountain region with state-of-the art cancer research, therapy, control, and educational programs.

- UCCC is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only such facility in the region
- UCCC is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2007
- Internationally recognized for work on prevention, early detection, and treatment of lung and chest cancer, and has a SPORE in lung cancer
- Named a LIVESTRONG Survivorship Center of Excellence by the Lance Armstrong Foundation
- Served more than 17,000 cancer patients and had 74,740 outpatients visits in 2006
- First and only nuclear magnetic resonance CORE facility
- Received a five-year award in September 2003 from the NCI and the NIA to accelerate and establish research addressing the relationship between aging and cancer
- Established a formal consortium in 2004 between the following regional institutions: The University of Colorado Denver and Health Sciences Center, University of Colorado, Boulder, the AMC Cancer Research Center, the National Jewish Medical and Research Center, and the Colorado State University Campus in Fort Collins, thus linking the effort of over 250 cancer scientists and clinicians
- Only center in the region to participate in the Early Detection Research Network, and manages the Colorado Colorectal Screening Program
- Working to reduce disparities of cancer incidence and to improve cancer prevention and control in Hispanic communities across Colorado

June 2008
The Carole and Ray Neag Comprehensive Cancer Center
University of Connecticut Health Center
Farmington, Connecticut (5th Congressional District)
HTTP://CANCER.UCHC.EDU/

Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The Carole and Ray Neag Comprehensive Cancer Center received $14.4 million in total funding from NCI in FY 2005.

The mission of the Carole and Ray Neag Comprehensive Cancer Center is to reduce the incidence and mortality of cancer through delivery of “state of the art” therapies community outreach and education; to foster basic, translational and clinical research; to pursue discoveries in cancer prevention, diagnosis and treatment; and to train future leaders in basic, translational and clinical cancer research.

- Accredited by the Commission on Cancer (COC) of the American College of Surgeons
- Participates in more than 70 clinical trials of new cancer treatments
- Provides Connecticut residents access to cutting-edge technology and therapy. The center is one of two sites in New England with a Tomotherapy unit for the delivery of radiation
- Launched Patient Navigator Program
- Developed novel screening and early diagnostic imaging program
- Developed novel vaccine therapies as part of the Cancer Immunology program
- Recognized as a leader in caring for patients with melanoma
- Brings together the resources of the University of Connecticut School of Medicine, the School of Dental Medicine and University of Connecticut, Storrs campus, including a Stem Cell Institute and Nanotechnology Center
- Launched a multidisciplinary Colon Cancer Prevention program in 2005
- Opened the Lea’s Center for Hematologic Disorders in 2007
- Partnered with the CT BHI, Inc and private philanthropy in developing a multidisciplinary women’s cancer program, with a focus in novel imaging, therapy and cancer prevention

June 2008
Yale Cancer Center received $30.7 million in total funding from the NCI in FY 2007, and has been an NCI-designated Cancer Center since 1974.

As part of an elite group of NCI-designated Cancer Centers, Yale Cancer Center scientists make important contributions to basic science, in addition to focusing on translational research. Yale Cancer Center emphasizes the molecular origins of cancer, stressing targeted treatments that are more specific to a particular cancer and less debilitating to patients.

- Yale Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only such facility in the state of Connecticut
- Yale Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 25 cancer hospitals in the United States in 2007
- Yale is best known as the institution where both cancer chemotherapy and the entire field of drug development were discovered
- Opened the Connecticut Challenge Survivorship Clinic in 2006, it provides specialized care for cancer survivors after finishing treatment
- The very first cancer drug was administered at this Center
- Almost 50 open and active clinical trials
- Transimmunization, the first FDA-approved selective immunotherapy treatment for any type of cancer, was developed at Yale
- Brings together the resources of Yale University School of Medicine, Yale-New Haven Hospital, and Yale University
- Studies focus on racial disparities in cancer and differences in survival rates

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The George Washington University Cancer Institute (GWCI) received $8.25 million in total funding from NCI in FY 2007.

The George Washington University Cancer Institute (GWCI) is an urban oncology center in the heart of Washington, DC, bringing trans-disciplinary clinical care, research, education, and outreach together in a comprehensive approach to cancer prevention, screening, diagnosis, treatment, and survivorship. The GWCI is dedicated to the elimination of cancer disparities in Metropolitan Washington, DC.

- Home to the East Coast AIDS and Cancer Specimen Bank, both NCI funded
- Operates the GW Mammovan, a mobile digital mammography program offering more than 2,500 mammograms to DC’s underserved community
- Launched the NCI-funded Oncogenomics of Cancer Disparities Center including the MORE (Minority Oncology Research and Education) Training Center
- Launched one of the first Cancer Health Policy programs in the country
- Conducts groundbreaking NCI and NIH-funded cancer research on stem cells and cancer, carcinogenesis, experimental therapeutics, genomics, computational cancer medicine, AIDS-related malignancies, parasite-related malignancies, inflammation and cancer, cancer imaging, clinical trials, and cancer prevention, and control and survivorship
- Conducts a comprehensive Community by Community Cancer Control Campaign with city-wide outreach. GWCI’s Men’s Oncology Program has achieved unprecedented success in prostate cancer screening among DC African Americans

June 2008
DISTRICT OF COLUMBIA

HOWARD UNIVERSITY CANCER CENTER
HOWARD UNIVERSITY

Washington, DC (District of Columbia Congressional District)
HTTP://CANCER.HOWARD.EDU/

Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Howard University Cancer Center (HUCC) received $2.15 million in total funding from NCI in FY 2005.

The Howard University Cancer Center (HUCC) aims to reduce the burden of cancer and to eliminate cancer-related health disparities among African Americans and other underserved populations through education, research, and state-of-the-art treatment.

- The HUCC is the only stand-alone cancer center at a historically Black college or university in the country
- Designated NCI Cancer Planning Center and regional contractor for NCI’s Cancer Information Service
- Designated NIH site for the Women’s Health Initiative
- Established low cost and free cancer screening programs for various cancers, such as breast and prostate
- Partnered with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University to create a long-term collaborative relationship for cancer research, training, education, and outreach focusing on cancers that disproportionately affect minority populations

June 2008
DISTRICT OF COLUMBIA

Lombardi Comprehensive Cancer Center
Georgetown University

Washington, DC (D.C. Congressional District)
HTTP://LOMBARDI.GEORGETOWN.EDU

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

| Lombardi Comprehensive Cancer Center received $26.7 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1990. |

The objective of the Lombardi Comprehensive Cancer Center at Georgetown University is to provide the most advanced treatments available to Lombardi patients, educate the next generation of cancer researchers and physicians and, ultimately, to find a cure for this devastating disease.

- The Lombardi Comprehensive Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only such facility in the DC area
- The Lombardi Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Lombardi is a founding member of the cancer biomedical informatics grid (caBIG), and was the first institution to receive a site visit from NCI
- Lombardi’s Capital Breast Care Center, located in underserved southeast DC, provides breast cancer screening to women regardless of their ability to pay
- Thanks to the Nina Hyde Center for Breast Cancer Research at Lombardi, home to over 30 top breast cancer researchers, Georgetown University is ranked 6th in the world for breast cancer research by ESI Thompson Scientific
- Research at Lombardi led to the world’s first cervical cancer vaccine
- Lombardi's internationally-renowned clinical team offers the latest treatments and clinical trials for virtually every type of cancer
- The Lombardi Institute for Quality of Life encourages patients experiencing difficult symptoms to work throughout their illness to achieve and maintain the highest possible quality of life
- Lombardi offers a PhD program in Tumor Biology, five masters programs, and postdoctoral training in both the laboratory and in hematology/oncology clinical practice
- A new Pediatric Cancer Research Program developed in collaboration with Children’s National Medical Center now complements the well-known Pediatric clinic at Lombardi

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Moffitt Cancer Center and Research Institute received $33.3 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1998.

As part of an elite group of NCI Comprehensive Cancer Centers, the mission of the H. Lee Moffitt Cancer Center and Research Institute is to contribute to the prevention and cure of cancer, working tirelessly in the areas of patient care, research, and education to advance one step further in fighting this disease.

- The Moffitt Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only such facility in the state of Florida
- The Moffitt Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Moffitt is known as a major research center with programs in Molecular Oncology; Drug Discovery; Immunology; Experimental Therapeutics; Health Outcomes and Behavior and Risk Assessment, Detection and Intervention
- Ranked by US News & World Report as one of the top 25 cancer hospitals in the United States in 2007
- Moffitt Cancer Center served 6,492 inpatients and recorded 232,060 outpatient visits in 2006
- Employs more than 2,900 people
- Houses the National Functional Genomics Center, which works to validate the concept that molecular signature in tumors predict cancer risk, diagnosis, prognosis and response to therapy, as well as identify new molecular targets for the development of more effective cancer prevention and personalized therapeutic care
- Moffitt’s Blood and Marrow Transplantation Program, established in 1989, is one of the largest programs in the Southeast, averaging more than 250 allogenic and autologous transplants a year
- Moffitt has clinical trials for many different organ systems and clinical programs, currently more than 207 active cancer trials

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

University of Florida Shands Cancer Center received $8.2 million in total funding from NCI in FY 2007

The University of Florida Shands Cancer Center (UFSCC) is dedicated to providing state-of-the-art cancer treatment, prevention, control, and education. The UFSCC conducts original scientific research aimed at discovering and comparing mechanisms of oncogenic and normal cell growth. UFSCC is committed to elucidating disease mechanisms, developing new and novel therapies while testing them via clinical trials, and delivering state-of-the-art care to cancer patients.

- One of the leading referral medical centers in southeastern part of the U.S.
- UFSCC’s internationally-renowned multidisciplinary clinical teams offer the latest treatments and clinical trials for virtually every type of cancer
- The new Cancer and Genetics Research Complex is 130,000 sq. ft. of state-of-the-art laboratories dedicated to cancer research (+130,000 sq. ft. for genetics research) - designed to maximize collaborations among different groups of researchers
- The University of Florida Proton Therapy Institute, located on the Jacksonville campus, is one of five treatment centers nationwide, and the only center in the Southeast
- Blood and Marrow Transplant Clinical Trials Network - one of 16 Core Clinical Centers in the NHBLI/NCI-sponsored network
- Pediatric Oncology Experimental Therapeutics Investigators Consortium. UFSCC is ranked sixth in the nation
- T-32 Training Grants in Cancer Biology and Surgical Oncology
- GMPs for gene therapy, cellular vaccine therapies, and novel drugs for various clinical trials
- Shands at UF Cancer Hospital will contain 180 beds dedicated to oncology, scheduled for completion in 2009
- Dedicated to training the next generation of scientists in a variety of fields

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) initiated the National Cancer Program to create an unparalleled network of leading cancer centers across the United States dedicated to eradicating cancer through comprehensive and multidisciplinary research programs in cancer prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated Cancer Centers and receive core grant funding from NCI. In addition, researchers within the larger network receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally recognized hubs of leading-edge research, high-quality cancer care, and outreach and education for health care professionals and the public. Many standard-of-care therapies and cures used today were first developed and investigated in many of these centers. The centers actively partner with community and state health agencies to bring life-saving discoveries to patients.

University of Miami Sylvester Comprehensive Cancer Center received $14.4 million in total funding from NCI in FY 2007.

University of Miami Sylvester Comprehensive Cancer Center (UM/Sylvester) seeks to reduce the human burden from cancer through research, education, prevention, and the delivery of quality patient care. The Center strives to provide new hope for cancer patients in its extended community, including South Florida, the southeastern United States, the Caribbean, and South America.

- Four multidisciplinary research programs with nearly 100 cancer center scientists and 120 affiliated physicians
- UM/Sylvester physicians are organized into 15 site disease groups to offer patients multidisciplinary site-based care
- Serves the most distinctive population in the country, characterized by ethnic and racial diversity (80 percent of Miami-Dade residents are black or Hispanic compared to 26 percent of U.S. residents) as well as significant disparity in socioeconomic status
- Approximately 200 clinical trials underway at any given time, accruing 1,000 patients per year
- The Regional Cancer Information Service office, funded by NCI, was established at UM/Sylvester; this is the only Spanish-language CIS in the country
- Serves nearly 4,000 new patients, conducts 200,000 outpatient visits, and 3,000 surgeries every year
- UM/Sylvester’s satellite facility in Deerfield Beach recently expanded to double its size to accommodate the Center’s growing number of patients in Broward and Palm Beach counties

June 2008
GEORGIA

MEDICAL COLLEGE OF GEORGIA CANCER CENTER

Augusta, Georgia (10th Congressional District)
HTTP://WWW.MCG.EDU/CANCER/

Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The Medical College of Georgia Cancer Center received $4.7 million in total funding from NCI in FY 2007.

The Medical College of Georgia Cancer Center (MCGCC) is charged with leading the cancer research and clinical care components of the MCG community in developing strong, cutting-edge basic, clinical, and translational research programs whose findings and activities reach into the community that we serve. MCGCC researchers and clinicians conduct cutting-edge research within tightly organized research programs and offer the latest, most promising therapeutic agents in their commitment to identify cures for patients. All activities are focused on the ultimate goal of reducing cancer morbidity and mortality.

- Provides comprehensive multidisciplinary clinical care with particular strength in breast, hematologic, genitourinary/prostate, thoracic, and gynecologic malignancies.
- Awarded an NCI-funded Minority-Based Community Clinical Oncology Program.
- Participates in over 160 clinical trials and supports a dedicated, Phase I/II clinical trials unit where patients receive the most innovative, cutting-edge treatment therapies that are only available at a select few cancer centers.
- Constructing a new free-standing Cancer Center Outpatient Facility, providing space for multidisciplinary examination rooms and ancillary services, along with a new Phase I/II clinical research unit and infusion center.
- Opened the Cancer Research Center (CRC), a state-of-the-art, 167,000 square foot, open laboratory facility that houses research activities in the dedicated programs of Cancer Immunology and Immunotherapy, Molecular Oncology, Developmental Therapeutics, and Cancer Prevention and Control.
- Participates with the Medical College of Georgia Center for Patient and Family Centered Care that incorporates patient-and family-centered principles into clinical cancer care.
- Home to the MCG Health System’s Georgia Radiation Therapy Center, the only high volume facility for radiation oncology in the region.

June 2008
GEORGIA

WINSHIP CANCER INSTITUTE
EMORY UNIVERSITY

Atlanta, Georgia (4th Congressional District)
HTTP://WWW.WINSHIPCANCERINSTITUTE.ORG/

Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Winship Cancer Institute received $56.7 million in total funding from NCI in FY 2006.

For more than 65 years, Emory Winship Cancer Institute has worked tirelessly to prevent, treat, and cure cancer. In the Winship facility, each of the seven floors is named for one of the core values that are embedded in the mission of the Institute: compassion, caring, courage, hope, imagination, translation, and discovery.

- NCI Cancer Center Planning Grant – Currently working toward NCI Comprehensive Cancer Center status, and this would be Georgia’s first NCI-designated comprehensive cancer center

- Strong supporter of and partners with the Georgia Cancer Coalition, working to unite Georgia’s leading hospitals, universities, biotech firms, civic groups, non-profit organizations, and government agencies in the fight against cancer

- Membership of nearly 150 members, including faculty from throughout Emory University, the Woodruff Health Sciences, and Georgia Tech

- The facility is located in Atlanta – one of the world’s most accessible international cities

- Researchers at Emory University’s Winship Cancer Institute were the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival. Their research may result in identification of a new therapeutic target for treating multiple myeloma

- NCI has awarded a five-year, $12.5 million Specialized Program of Research Excellence (SPORE) grant in head and neck cancer to Emory University’s Winship Cancer Institute. This is the first SPORE grant ever received in the state of Georgia

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The CRCH is the only NCI-designated Cancer Center in the State of Hawaii and serves as a focal point for public information on the latest in cancer-related knowledge

The CRCH is one of 63 cancer centers in the national network of NCI-designated Cancer Centers

Operates the Hawaii Cancer Information Service, Pacific Region and maintains close ties with other health organizations to provide information

Employs more than 250 staff, including 68 physicians and scientists as members of the cancer center faculty

Participates in more than 100 clinical trials at any given time

Conducts research on the causes, prevention, and treatment of cancer

Cancer Research Center of Hawaii (CRCH) received $18.6 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1996.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Cancer Research Center of Hawaii (CRCH) is to reduce the burden of cancer through research, education, and service with an emphasis on the unique ethnic, cultural, and environmental characteristics of Hawaii and the Pacific.

- The CRCH is the only NCI-designated Cancer Center in the State of Hawaii and serves as a focal point for public information on the latest in cancer-related knowledge
- The CRCH is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Operates the Hawaii Cancer Information Service, Pacific Region and maintains close ties with other health organizations to provide information
- Employs more than 250 staff, including 68 physicians and scientists as members of the cancer center faculty
- Participates in more than 100 clinical trials at any given time
- Conducts research on the causes, prevention, and treatment of cancer
- The Clinical Trials Unit of the CRCH administers state-of-the-art cancer clinical treatment trials statewide, conducting studies designed to reduce cancer incidence among the general population
- Provides training opportunities related to an array of cancer topics to a variety of educational levels
- Operates the Hawaii Tumor Registry which maintains a database of information on all cases of cancer diagnosed in Hawaii since 1960, providing complete cancer reporting for the entire state, and serving as a resource for cancer prevention and cancer control activities
Under the National Cancer Act of 1971, our national cancer program, led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, highly quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Cardinal Bernardin Cancer Center received $3.18 million in total funding from NCI in FY 2007

The Cardinal Bernardin Cancer Center was the first free-standing facility in Illinois dedicated to cancer research, diagnosis, treatment, and prevention. One of the hallmarks of the Cardinal Bernardin Cancer Center is its emphasis on an interdisciplinary approach to both clinical care and research, which is most evident in its seven multidisciplinary clinics addressing breast care, gastrointestinal oncology, head and neck oncology, melanoma, neuro-oncology, radiosurgery, and thoracic (lung) oncology.

- Provides more than 50,000 physician visits and 22,000 patient treatment visits per year
- More than 100 active clinical research trials are being conducted
- The bone marrow transplantation program is one of the largest in the nation and performs the most transplants in the state of Illinois, including umbilical cord blood transplants and other unique and advanced services
- The Coleman Image Renewal Center provides unique image-related services (e.g. hair replacement, cosmetics, prostheses fitting) and complementary therapies specifically targeted to the cancer patient
- The pancreatic surgery program is one of the most experienced in the country
- An ongoing vaccine development program investigating innovative therapies for pancreatic, ovarian, melanoma, and other cancers
- The cellular therapy research program explores stem cell therapies utilizing stem cells from adult and umbilical cord blood
- Programs designed for the community and the underserved include prostate and skin cancer screening programs, cancer patient support groups, Access to Care for the neighboring communities, CAN-HELP Cancer Information Service call line, and other programs

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Robert H. Lurie Comprehensive Cancer Center received $35.0 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1993.

As part of an elite group of NCI-designated comprehensive Cancer Centers, the Lurie Cancer Center is dedicated to scientific discovery, advancing medical knowledge, providing compassionate, state-of-the-art cancer care, and training the next generation of clinicians and scientists. To this end, the Cancer Center leadership aggressively encourages and supports multi-programmatic and multidisciplinary research.

- The Lurie Comprehensive Cancer Center is one of only 39 NCI-designated comprehensive cancer centers in the nation, and the only such facility in the state of Illinois

- The Lurie Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers

- Founding member of the National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers that defines and sets national standard for cancer care

- 235 clinicians and scientists are actively involved in cancer care and research

- Extramural cancer relevant research funding exceeds $115 million annually

- Awarded an NCI Patient Navigation grant in 2005, one of only nine in the country

- SPORE in prostate cancer

- Received five-year grant in 2005 from the NCI to establish a Center for Cancer Nanotechnology Excellence, one of seven in the country

- Northwestern’s Institute for Women’s Health Research was recipient of a $21 million NIH Roadmap for Medical Research grant to develop an Oncofertility Consortium which will offer research, clinical and education programs that target fertility threats posed to women by cancer treatment

- Internationally-renowned clinical team offers the latest treatments for virtually every type of cancer

- On average more than 250 therapeutic clinical trials are available to patients

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The SimmonsCooper Cancer Institute at SIU received $6.6 million in total funding from NCI in FY 2006.

The SimmonsCooper Cancer Institute serves the people of central and southern Illinois by addressing their present and future cancer care needs through a comprehensive approach of education, research and patient services. The Cancer Institute’s charge includes working to upgrade the standard of cancer care in downstate Illinois communities. SimmonsCooper Cancer Institute is the academic cancer center of Southern Illinois University with multidisciplinary patient care, extensive clinical cancer research, and new programs in translational cancer research. We are educators for physicians and our community in cancer, and a vital resource for central and southern Illinois.

- The largest academic cancer program in downstate Illinois comprised of 60 professional members
- Sponsorship of organ site working groups to provide multidisciplinary care for patients with cancer of the breast, lung, prostate, colorectal, head and neck, pediatric age, gynecologic organs, and skin
- Approximately 20 independent cancer research programs led by SIU faculty at SIU Springfield and SIU Carbondale
- More than 100 active clinical research trials are being conducted for patients with various types of cancer
- Provides second opinions and tertiary care for patients throughout central and southern Illinois
- Strong partnerships with Memorial Medical Center and St John’s Hospital
- Sponsorship of a multitude of outreach events, screenings, and education venues reaching thousands of citizens and health care professionals

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The University of Chicago Cancer Research Center received $43.7 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1973.

As part of an elite group of NCI-designated Cancer Centers, the mission of the University of Chicago Cancer Research Center is to understand, cure, and prevent each of the scores of diseases collectively called cancer.

- The University of Chicago Cancer Research Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 10 cancer hospitals in the United States in 2007
- More than 200 renowned scientists and clinicians who conduct more cancer clinical trials than in any other institution in Illinois and surrounding states
- Home to the Center for Interdisciplinary Health Disparities Research, a collaborative approach to examine population health and to evaluate and eliminate group differences in health
- Collaboration with the University of Illinois at Chicago to advance the field of health promotion through training and research in economic analysis
- Leaders in development of anticancer drugs and the emerging field of pharmacogenomics
- Researchers at this institute were instrumental in the development of bone marrow transplantation, administered the first successful chemotherapy, performed fundamental work in hormonal therapy for prostate and breast cancers, and first proved the link between cancers and genetic disorder enabling the development of effective chemotherapies for treating leukemia
- Home of the Cancer Risk Clinic and High-Risk Upper Aerodigestive Malignancies Clinic, diagnostic and preventive care programs where teams of experts work closely with patients and their families assessing risk and developing strategies for prevention
- In 2006, awarded a SPORE grant for breast cancer from the NCI and a Specialized Center of Research grant from the Leukemia and Lymphoma Society

June 2008
I L L I N O I S

U N I V E R S I T Y O F I L L I N O I S C A N C E R C E N T E R
U N I V E R S I T Y O F I L L I N O I S A T C H I C A G O

Chicago, Illinois (7th Congressional District)
HTTP://UILLINOISMEDCENTER.ORG/CONTENT.CFM/CANCER_CENTER

Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

University of Illinois Cancer Center received $20 million in total funding from NCI in FY 2006.

The mission of the UIC Cancer Center is to: (1) reduce the burden of cancer on the people of Illinois and beyond through an integrated program of excellence in research and education on the causes, prevention, and treatment of cancer; (2) translate the knowledge gained from this research into improved cancer prevention, detection, treatment and quality of life; and (3) reach all people of Illinois, including those experiencing disparities in cancer prevention, early detection, treatment, and supportive services post-treatment.

- One of only a handful of universities in the country with six health sciences colleges on one campus and the only university in the greater Chicago area with a College of Medicine (COM), School of Public Health, College of Pharmacy, College of Dentistry, College of Nursing, and College of Applied Health Sciences
- A matrix center with 120 members
- Total of $32 million in cancer-related and peer-reviewed external funding was awarded during FY06
- Serves 1,200 cancer patients annually
- Participates in more than 90 cancer clinical trials
- 80% of patients come from throughout the city of Chicago, with the highest concentration from the West, Southwest, and Far South regions
- Awarded an NCI-funded Minority-Based Community Clinical Oncology Program that increases access to NCI-sponsored clinical trials for medically underserved minority communities
- Awarded an NCI grant to establish a Center for Population Health and Health Disparities

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Indiana University Simon Cancer Center received $11.7 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1999.

IU Simon Cancer Center advances the understanding, prevention and treatment of cancer throughout Indiana and the world with patient-centered care, acceleration of promising science, and collaborative educational programs.

- The Indiana University Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Serves nearly 38,000 patient and 4,100 inpatient visits each year
- Established the Indiana Cancer Consortium in collaboration with the American Cancer Society-Great Lakes Division and the Indiana State Department of Health. This statewide network is dedicated to reducing the cancer burden through a cancer-control plan
- The IU Simon Cancer Center’s 228 members teach nearly 2,000 students, residents, and fellows and sponsor several post-graduate educational programs each year
- In NIH-funded studies, IU Simon Cancer Center members made critical observations that led to the use of umbilical cord stem cells for transplantation
- NIH-funded IU Simon Cancer Center investigators have made unique observations about tamoxifen, a drug widely used to treat breast cancer. Physicians can now predict which patients are more or less likely to respond to the drug and the potential to design treatment for women worldwide
- The IU Simon Cancer Center is home to major cancer treatment successes such as the curative chemotherapy regimen for testis cancer discovered by Lawrence H. Einhorn, M.D., that has saved the lives of more than 100,000 young men, including cyclist Lance Armstrong
- Physician scientists at this center were the first to study bevacizumab – an antibody that prevents the growth of blood vessels, which encourages the spread of cancer cells. This has resulted in the routine use of this drug to treat breast, lung and colon cancer

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Purdue University Cancer Center received $9.5 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1978.

As part of an elite group of seven NCI-designated Cancer Centers that focuses exclusively on laboratory research, the Purdue Cancer Center is committed to helping cancer patients by identifying new molecular targets and designing future agents and drugs for effective detection and treatment of cancer. While the Purdue Cancer Center does not provide patient care, it does focus on basic research that leads to innovative discoveries in cancer research that become part of the standard practice in cancer research and patient treatment.

- The Purdue Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- The Purdue Cancer Center is a basic laboratory center, and does not provide clinical services to patients
- The Center helped establish the Indiana Cancer Consortium, a statewide network of public and private organizations dedicated to collaboratively reducing the cancer burden through the development and implementation of a state cancer control plan
- Home to 82 scientists on its research faculty from 11 departments and six colleges at Purdue University
- The Purdue Cancer Center is one of two NCI-designated Cancer Centers in the state of Indiana
- Researchers at Purdue Cancer Center are using nanotechnology (building tiny structures atom-by-atom) to create tiny sensors for the detection of cancer biomarkers, or “clues to cancer,” in a single drop of blood
- The Center provides a forum for Purdue’s best and brightest scientists to collaborate across campus and nationwide to attack the cancer problem

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Holden Comprehensive Cancer Center received $14.0 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 2000.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Holden Comprehensive Cancer Center at the University of Iowa is to decrease the pain and suffering caused by cancer in Iowa, the Midwest, and beyond through improved cancer prevention and treatment based on the three interdependent missions of research, clinical service, and education.

- The Holden Comprehensive Cancer Center is one of only 39 NCI-designated comprehensive cancer centers in the nation, and the only one in the state of Iowa
- The Holden Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Holden Comprehensive Cancer Center has a SPORE for lymphoma
- More than 175 Cancer Center members in 26 departments and six colleges
- Received a five-year grant in September 2003 from the NCI and the National Institute on Aging to accelerate research into the relationship between aging and cancer
- Provides cancer information to patients and their families through the Cancer Information Service
- Conducts a broad range of research that addresses cancer prevention, early detection and therapy for multiple types of cancer through research programs in Cancer Immunology and Immunotherapy, Cell Signaling and Developmental Pharmacology, Free Radical Cancer Biology, Cancer Epidemiology, Cancer Genetics, and Computational Biology
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary programs of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high-quality cancer care, and outreach and education for healthcare professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The University of Kansas Cancer Center (KUCC) is dedicated to reducing the burden of cancer on the Heartland by building a world-class cancer center that is at the forefront of drug discovery and development, clinical research in early detection, prevention, treatment, and survivorship; and improve access to clinical trials and cancer advancements throughout the region.

- Developed and currently implementing a strategic business plan to obtain NCI designation within the next decade.
- Recruited top pharmaceutical industry professionals for Deputy Director of OTDD and Director of High Throughput Screening.
- Created the Midwest Cancer Alliance (MCA), the outreach arm of KUCC. The MCA is a membership-based organization bringing cancer research, care and support professionals together to advance the quality and reach of cancer prevention, early detection, treatment, and survivorship in the Heartland.
- Participates in or leads 140 clinical trials.
- KUCC served 1,712 patients in 2005 from Kansas, Missouri, and other states.
- The Office of Therapeutics, Discovery, and Development (OTDD) is a key component of KUCC and plays an important role in their quest for NCI designation. Researchers, centers, and industry partners collaborate in a highly integrated and organized environment to support the creation and advancement of cancer projects.
- Val Stella, Drug Discovery, and Experimental Therapeutics program co-leader renewed a contract with NCI to develop drug formulations on promising new cancer agents advanced through NCI’s pipeline.
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The James Graham Brown Cancer Center, at the University of Louisville, is affiliated with the National Cancer Institute and is making great strides with an aggressive plan to become a NCI-designated Cancer Center. The Brown Cancer Center scientists focus on translational research, with emphasis on molecular targets, structural biology, tumor immunobiology, stem cell biology, and prevention and control.

- Development of the first oligonucleotide aptamer used to treat cancer patients
- Currently, the Brown Cancer Center is conducting more than 80 clinical trials
- Led one of the nation’s largest studies on melanoma (Sunbelt Melanoma Trial) and the NCI’s Melanoma Vaccine Trials
- Development of the first tobacco-produced cancer vaccine for human cancer.
- The Brown Cancer Center is building a state-of-the-art Biomedical Research Building, scheduled to open in 2009
- Awarded $12 million over six years to create the Kosair Charities Pediatric Cancer Research Center—a world-class research center with the specific goal of developing new drugs that target children’s cancer
- Awarded a National Institutes of Health Center of Biomedical Research Excellence in Molecular Targets grant in 2001
- Kentucky continues to bear a disproportionate burden of cancer incidence, especially in lung cancer. The Kentucky Lung Cancer Research Program – jointly administered by the James Graham Brown Cancer Center at the University of Louisville, and the Lucille Parker Markey Cancer Center at the University of Kentucky – is a unique program organized to find ways to alleviate this burden
- The Kentucky Cancer Program (KCP) is a nationally recognized program, which promotes cancer education, research, and service programs to reduce cancer incidence and mortality across the Commonwealth of Kentucky

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The Lucille P. Markey Cancer Center received $9.3 million in total funding from NCI in FY 2006.

The Markey Cancer Center’s mission is to reduce the morbidity and mortality from cancer through a comprehensive program of cancer education, research, patient care and community outreach activities. The Markey Cancer Center stresses a team approach to cancer treatment. Patients and families are central members of this team. Other members of the team include doctors, a primary nurse, oncology nurse care manager, dietitian, social worker, pharmacist, chaplain, volunteers and, if needed, a physical or enterostomal therapist.

- The Kentucky Lung Cancer Research Program, jointly administered by the Markey Cancer Center and the James Graham Brown Cancer Center, is charged with reducing the burden of lung cancer in Kentucky
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2007
- The Kentucky Cancer Program, jointly administered with the James Graham Brown Cancer Center, offers public and professional education throughout the Commonwealth
- Manages the NCI’s six-state mid-south Cancer Information Service research and educational components and the Marty Driesler Cancer Project that conducts community-based research in eastern and southeastern Kentucky
- Currently, conducting more than 100 clinical trials
- More than 150 faculty from 28 departments of 8 different colleges of the University of Kentucky are members of the Markey Cancer Center
- The Kentucky Cancer Registry based at Markey is now part of the NCI SEER program, collecting and analyzing data from more than 20,000 new cancer cases annually
- Specialized offerings at the Markey Cancer Center include: a Blood and Marrow Transplant Program; Gamma Knife; cellular immunotherapy for lung cancer; innovations in thyroid and neurologic cancers; ovarian cancer screening; minimally invasive surgery; sentinel node mapping

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The Louisiana Cancer Research Consortium in New Orleans is a cancer research partnership between Louisiana State University’s Stanley S. Scott Cancer Center and Tulane University Health Sciences Center’s Tulane Cancer Center — the state’s two leading academic medical research institutions. They are joined by Xavier University of Louisiana, with research focusing on health disparities and education.

- These institutions work together to coordinate cancer research development in preparation for recognition as an NCI-designated cancer center
- Founded by the Louisiana State Legislature in 2002, the LCRC is dedicated to developing a coordinated research and education program that will optimize discovery and development of innovative cancer therapies that lead to more effective opportunities for early detection, treatment, and prevention of cancer in the region
- Approximately 230 cancer researchers collaborate across five research programs, including cancer genetics, immunology, cell signaling, population sciences, and clinical research
- Together, these scientists secured approximately $19 million in cancer research support from the NCI, the Department of Defense, and other federal funding agencies
- LCRC researchers are supported by the following Core facilities: Biospecimen Core, Biostatistics Core, Cell Analysis/Immunology Core, Genomics, Imaging and Proteomics

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Jackson Laboratory received $4.0 million in total funding from the NCI for FY 2007, and it has been an NCI-designated Cancer Center since 1983.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Jackson Laboratory is to improve the quality of human life through discoveries arising from genetic research and by enabling the research and education of others. While the Jackson Laboratory does not provide patient care, it does focus on basic research that leads to innovative discoveries in cancer research that become part of the standard practice in cancer research and patient treatment.

- The Jackson Laboratory is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- The Jackson Laboratory is a basic laboratory center, and does not provide clinical services to patients
- Leads the way in using the mouse as a model to research human cancers and cancer treatments
- Established collaborative programs in systems biology, nanoscience, and translational research to understand the biology of cancer and translate this knowledge to the bedside
- Conducts research on brain, bone, cervical, liver, mammary and ovarian cancers, leukemia, and lymphoma. Research focuses on understanding fundamental mechanisms of cancer initiation and progression in the context of mouse biology and genomics
- The Jackson Laboratory Cancer Center includes 59 members and their research staffs
- Hosts a variety of courses and conferences designed to maximize professional scientific interaction for students and established cancer researchers alike. In 2006, approximately 1,200 scientists from around the world participated in these programs, with total offerings of 21 courses, workshops, and meetings
- Research training and education opportunities include a postdoctoral training program; internationally attended courses, conferences and workshops; and research internships for high school and college students and Maine in-service science teachers and science teachers-in-training
Maryland

The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University

Baltimore, Maryland (7th Congressional District)
HTTP://WWW.HOPKINSKIMMELCANCERCENTER.ORG

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Sidney Kimmel Cancer Center received $77.6 million in total funding from the NCI in FY 2007, and has been an NCI-designated Cancer Center since 1973.

As part of an elite group of NCI-designated Cancer Centers, the dedication of The Sidney Kimmel Cancer Center at Johns Hopkins University is to better understand human cancers and find more effective treatments.

- The Sidney Kimmel Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only one in the state of Maryland
- The Sidney Kimmel Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 5 cancer hospitals in the United States in 2007
- The Sidney Kimmel Cancer Center has seven SPOREs: breast cancer, gastrointestinal cancers, gynecologic cancers, head and neck cancers, lung cancer, lymphoma and prostate cancer
- More than 3,000 bone marrow transplants have been performed at this Center
- Leads or participates in 225 open and active clinical trials in many tumors, including pancreas, breast, brain, head and neck, colorectal and prostate cancers
- More than 6,000 newly diagnosed and treated cancer patients entering the Center annually
- Internationally known for its dedication to the relief of cancer pain
- According to Science Watch, the Center is home to the top five researchers in the field of oncology
- Patient and family education program to assist in providing optimal care
- Home to the Ovarian Cancer Center of Excellence, committed to a multi-disciplinary approach for treating ovarian cancer

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) initiated the National Cancer Program to create an unparalleled network of leading cancer centers across the United States dedicated to eradicating cancer through comprehensive and multidisciplinary research programs in cancer prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated Cancer Centers and receive core grant funding from NCI. In addition, researchers within the larger network receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally recognized hubs of leading-edge research, high-quality cancer care, and outreach and education for health care professionals and the public. Many standard-of-care therapies and cures used today were first developed and investigated in many of these centers. The centers actively partner with community and state health agencies to bring life-saving discoveries to patients.

University of Maryland Greenebaum Cancer Center (UMGCC) received $13.8 million in total funding from NCI in FY 2007.

University of Maryland Greenebaum Cancer Center (UMGCC) is a national leader in offering innovative approaches to basic and clinical research that will impact the understanding and treatment of cancer around the world. With comprehensive programs for treating all types of cancer, UMGCC is a major referral center and provides state-of-the-art clinical care to cancer patients throughout the state of Maryland and the region.

- New submission for an NCI-designated Cancer Center
- Invented and developed aromatase inhibitors which have represented a critical advance in the treatment of breast cancer worldwide
- More than 2,200 new patients are treated annually
- Patient navigator program to assist patients needing psychosocial resources, through a unique partnership with the American Cancer Society
- 30,000 outpatient visits per year in the modern outpatient facility—the Roslyn and Leonard Stoler Pavilion
- Outreach to thousands of uninsured Baltimore residents with free cancer screening supported by the Maryland Cigarette Restitution Fund Program
- Conducts more than 200 cancer-specific clinical trials with more than 900 patients enrolled annually and a leader in minority participation
- More than 168 scientists and clinical investigators, many of them nationally recognized cancer experts
- Receives more than $47 million a year in research grant funding

June 2008
MASSACHUSETTS

DANA-FARBER/HARVARD CANCER CENTER

Boston, Massachusetts (8th Congressional District)
HTTP://WWW.DFHCC.HARVARD.EDU

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Dana-Farber/Harvard Cancer Center received $218.2 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1973.

As part of an elite group of NCI-designated Cancer Centers, the initiatives of the Dana-Farber/Harvard Cancer Center (DF/HCC) encompass specific areas of development important to the Center’s mission, including Strategic Research Initiatives and the Initiative to Eliminate Cancer Disparities.

- The Dana-Farber/Harvard Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only one in the state of Massachusetts
- DF/HCC is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 5 cancer hospitals in the United States in 2007
- The Center has seven SPOREs: breast cancer, lung cancer, myeloma, ovarian cancer, prostate cancer, renal cancer, and skin cancer
- Currently conducting more than 650 adult and pediatric therapeutic clinical trials
- Employs more than 875 physicians and scientists
- The Dana-Farber Cancer Institute was named a LIVESTRONG Survivorship Center of Excellence by the Lance Armstrong Foundation
- Established a formal consortium in 1999 by integrating the cancer research and clinical activities of the following institutions: Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Beth Israel Deaconess Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Brigham and Women's Hospital
- More than 40 projects underway to understand the causes of disparities in cancer in underserved populations

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Boston University Cancer Research Center received $8.44 million in total funding from NCI in FY 2005.

Boston Medical Center (BMC), a private, not-for-profit, academic medical center located in Boston’s historic South End, was formed through a 1996 merger of Boston City Hospital, Boston Specialty and Rehabilitation Hospital and Boston University Medical Center Hospital. Consistent with its universal access mission to provide “consistently excellent and accessible health services to all in need of care, regardless of status or ability to pay,” BMC provided more than $294 million in free care to the uninsured in fiscal year 2006. BMC is the largest provider of free care in Massachusetts, serving a predominantly minority and low-income population, including many non-English speaking citizens and immigrants. As part of our commitment to provide exceptional cancer care to the city’s most vulnerable populations, we recently opened the J. Joseph Moakley Building; it houses the continuum of ambulatory cancer care services at BMC – from diagnostics and screening to treatment of local or advanced malignancies, as well as ambulatory surgery suites.

- During 2006, there were a total of 165 registrations onto oncology clinical trials with minorities accounting for 39% of the patients enrolled.
- Currently have more than 150 active clinical trials
- Expanded the Cancer Survivorship Program to include nine cancer support groups in addition to other services and events
- The Autologous Stem Cell Transplant Program at BMC is internationally recognized as a leader in the treatment of AL amyloidosis
- BMC’s Prostate Cancer Screening Initiative has screened 3,509 men during 119 community events. The program, begun in 2000, is the only prostate cancer screening program of its kind in Boston.
MASSACHUSETTS

CENTER FOR CANCER RESEARCH
MASSACHUSETTS INSTITUTE FOR TECHNOLOGY

Cambridge, Massachusetts (8th Congressional District)
HTTP://WEB.MIT.EDU/CCR

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

MIT Center for Cancer Research received $35.4 million in NCI total funding for FY 2007, and has been an NCI-designated Cancer Center since 1974.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Center for Cancer Research at MIT is to apply the tools of basic science and technology to determine how cancer is caused, progresses and responds to treatment. Through this effort, they have developed an increasingly complete understanding of the nature of cancer cells, which has led directly to improved treatments for the disease. While the Center for Cancer Research at MIT does not provide patient care, it does focus on basic research that leads to innovative discoveries in cancer research that become part of the standard practice in cancer research and patient treatment.

- The MIT Center for Cancer Research is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- The MIT Center for Cancer Research is a basic laboratory center, and does not provide clinical services to patients
- The Center currently has 33 members, including two Nobel laureates, 14 members of the National Academy of Sciences, and six Howard Hughes Medical Institute Investigators
- Employs 200 staff, including more than 50 postdoctoral fellows, more than 40 graduate students, and approximately 20 undergraduate students
- Contributed to the sequencing of the human genome by identifying the first oncogene
- Identified the molecules that led to the two first FDA-approved molecularly-targeted anticancer drugs, Herceptin and Gleevec
- The Center administers the MIT-Harvard Center for Cancer Nanotechnology Excellence, one of only seven funded by the NCI, to pursue nanotechnology that will enable cancer detection and monitoring
- Home to a symposium each spring that focuses on cutting-edge research that holds new promise for understanding and conquering disease
- Administrates the Ludwig Center for Molecular Oncology at MIT which has enabled researchers to launch a major attack on the fundamental problem of cancer metastasis

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Originally founded in 1976, the Tufts Medical Center Cancer Center has a long and rich tradition of providing the highest quality of cancer care that is compassionate and multidisciplinary combined with leading edge clinical and basic science research. Having pioneered the notion of multidisciplinary care, the Center combines the expertise of medical oncologists, surgical specialists, and radiation oncologists in treatment planning and implementation. The Centers staff is devoted to addressing each patient’s physical, emotional, and psychological needs.

- Tufts Medical Center offers a wide range of clinical services such as bone marrow transplantation, pediatric-hematology, otolaryngology and urology.
- Currently, the Tufts Medical Center is conducting over 50 clinical trials.
- Tufts Medical Center offers scientists and physicians training opportunities to work on different phases of cancer through programs in biomedical, nutritional science and medical centers.
- Tufts Medical Center’s MORI (Molecular Oncology Research Institute) explores neoplastic transformations.
- Current research programs include: Hematologic Malignancies; Cell Biology & Signaling, Measurement, Outcomes, & Biostatistics; Structural & Chemical Biology; Genetic Models in Development & Cancer; Nutrition & Cancer.
MICHIGAN

BARBARA ANN KARMANOS CANCER INSTITUTE
WAYNE STATE UNIVERSITY

Detroit, Michigan (13th Congressional District)
HTTP://WWW.KARMANOS.ORG

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Barbara Ann Karmanos Cancer Institute received $20.4 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1978.

As part of an elite group of NCI-designated Cancer Centers, the Barbara Ann Karmanos Cancer Institute is committed to a future free of cancer. Through research, patient care and education, Karmanos is dedicated to the prevention, early detection, treatment and eventual eradication of cancer.

- The Karmanos Cancer Institute is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- The Karmanos Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Serves cancer patients throughout Michigan and the Midwest.
- More than 6,000 new patients seek diagnosis and treatment annually
- Conducts more than 700 cancer-specific investigation programs and clinical trials
- As a leader in the field, the Karmanos Phase I Clinical Trials program is one of the best in the nation. Many of the cancer treatments most recently approved by the FDA had their initial testing here at Karmanos
- Receives more than $45 million a year in research grant funding
- Karmanos scientists are engaged in hundreds of research studies, from studying the level of copper in the human body, and its effect on prostate cancer, to identifying biomarker assays for earlier disease identification
- Employs more than 1,000 staff, including nearly 300 faculty members from Wayne State University
- Preferred hospital for cancer care by the National Research Corporation Ranked as metropolitan Detroit’s most

June 2008
MICHIGAN

VAN ANDEL INSTITUTE

Grand Rapids, Michigan (3rd Congressional District)
HTTP://WWW.VAI.ORG/

Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Van Andel Institute (VAI) received over $1.3 million in total funding from NCI in FY 2006.

Established in 1996, the Van Andel Institute (VAI) supports Van Andel Research Institute (VARI) and Van Andel Education Institute (VAEI) to fight disease through biomedical research and to inspire future scientists through education. With its collaborative focus promoting local, regional, national, and international partnerships, VAI helped drive the expansion of the life science industry in West Michigan.

VARI is an independent, world-class medical research facility that has gained worldwide recognition for basic and translational research into the genetic and molecular origins of cancer, Parkinson’s, Alzheimer’s and other diseases. VARI works to translate discoveries into therapies that will one day conquer illness and enhance lives. Through one recently-established protocol, VARI research provides clinical partners the opportunity to match uniquely-tailored drug treatments to the molecular makeup of individual patients. Since cancer is often unique to each individual, this “personalized medicine” has the potential to be a very powerful tool in the future of cancer treatment.

- VAI’s 240,000-square-foot Phase II expansion scheduled to be completed in late 2009 will not only allow a broader research focus, it will allow space for 550 new jobs that will increase the pace of research for VARI investigators as well as for students from VAI Graduate School and Michigan State University’s new College of Human Medicine
- Through world-class basic and translational research and life-changing educational programs, VAI is committed to finding solutions to the looming health threats of the 21st century
- VAEI’s Science Academy has initiated three major programs to engage students, teachers, and community members in science and promote science-related fields for all children, regardless of gender, race, or socioeconomic status
- The newly-founded Van Andel Institute Graduate School offers a unique, hands-on Ph.D. program to prepare students for careers in cell and molecular biology

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The University of Michigan Comprehensive Cancer Center received $62.8 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1988.

As part of an elite group of NCI-designated Cancer Centers, the mission of the University of Michigan (U-M) Comprehensive Cancer Center provides its patients comprehensive diagnostic, treatment and support services in an environment that reflects its mission: the conquest of cancer through innovation and collaboration.

- The U-M Comprehensive Cancer Center is one of only 39 NCI-designated comprehensive cancer centers in the nation
- The U-M Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by *US News & World Report* as one of the top 25 cancer hospitals in the United States in 2007
- U-M cancer researchers developed many leading cancer therapies, including Bexxar, organ-sparing surgery for head and neck and other cancers, and three-dimensional conformal radiation therapy
- SPOREs in head and neck cancers, prostate cancer and health communications
- More than 200 active clinical trials
- U-M researchers are at the forefront of novel research involving cancer stem cells, the small number of cells that fuel a tumor’s growth.
- Founding member of the National Comprehensive Cancer Network, an alliance of the leading cancer centers that defines and sets national standards for cancer care
- The center’s 369 physicians and researchers receive approximately $82.5 million in grants each year from NIH and other agencies
- Nearly 110,000 outpatient visits/infusions and 4,521 adult cancer patients admitted to the center annually – more than any other hospital in Michigan
- Patient support includes more than 30 programs and services

June 2008
MINNESOTA

MAYO CLINIC CANCER CENTER

Rochester, Minnesota (1st Congressional District)
HTTP://CANCERCENTER.MAYO.EDU

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Mayo Clinic Cancer Center received $62.1 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1973.

As part of an elite group of NCI-designated Cancer Centers, the mission of Mayo Clinic Cancer Center is to provide the best care to every patient every day through integrated clinical practice, education, and research.

- Mayo Clinic Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- Mayo Clinic Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 5 cancer hospitals in the United States in 2007
- The Center has six SPOREs: brain cancer, breast cancer, lymphoma, myeloma, pancreatic cancer, and prostate cancer
- Serves as the research base for the North Central Cancer Treatment Group, an NCI-sponsored national clinical research group founded in 1977
- Mayo Clinic’s Native CIRCLE program provides cancer-related resources to individuals involved in the education, care, or treatment of American Indians and Alaska Natives
- Onsite Cancer Education Center serves as a resource for cancer-related issues, and houses several on-site Patient Navigators
- The Nicotine Dependence Center conducts scientific research and uses proven findings to provide treatment in four areas, including behavioral treatment, addictions treatment, pharmacotherapy, and relapse prevention
- Treats more than 19,000 new cancer patients every year and conducts more than 6,800 clinical trials
- Serves as the research base for the Cancer Prevention Network, a consortium funded by the NCI
- Mayo Clinic Cancer Center investigators conduct research through worldwide collaborations, including with other NCI cooperative groups such as the Children’s Oncology Group

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The University of Minnesota Cancer Center received $33.5 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1998.

As part of an elite group of NCI-designated Cancer Centers, the University of Minnesota Cancer Center focuses on the causes, prevention, detection, and treatment of cancer; applying that knowledge to improve the quality of life for patients and survivors; and sharing its discoveries with other scientists, students, and medical professionals.

- The University of Minnesota Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- The University of Minnesota Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by *US News & World Report* as one of the top 25 cancer hospitals in the United States in 2007
- Includes more than 400 faculty and staff
- Led research that helped increase childhood cancer survival rates
- Opening in 2007, the Hope Lodge will provide accommodations for patients and family during cancer treatment
- Performed the world’s first successful bone marrow transplant for malignant lymphoma
- Conducted the first study to identify the presence of tobacco-specific carcinogens in non-smokers exposed to environmental tobacco smoke
- Created the first animal model for studying and disabling cells responsible for causing bone cancer pain
- In 2006, members received more than $90 million in national research grants
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Siteman Cancer Center received $39.2 million in total funding from the NCI for FY 2007, and received NCI-designated Cancer Center in 2005.

As part of an elite group of NCI-designated Cancer Centers, the mission the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is to reduce the impact of cancer today and eliminate the threat of cancer tomorrow.

- Siteman Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation and the only one in the state of Missouri
- Siteman Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by U.S. News & World Report as one of the top 25 cancer hospitals in the United States in 2007
- Siteman is a member of the elite National Comprehensive Cancer Network, an alliance of 20 of the nation’s leading cancer centers that defines and sets national standards for cancer care
- Scientists and physicians affiliated with Siteman hold $130 million in cancer research and related training grants
- About 350 clinical trials in progress at the Siteman Cancer Center
- Treats nearly 6,000 newly diagnosed cancer patients and more than 32,000 follow-up patients each year with all types of cancer focusing on a multidisciplinary approach to treatment
- Nationally recognized for clinical programs in leukemia and lymphoma as well as breast, gastrointestinal, head and neck, and genitourinary cancers
- Sponsors the Program for the Elimination of Cancer Disparities, which strives to reduce barriers to cancer education, care, and research for underserved groups
- Siteman’s Bone Marrow Transplant Program is one of the largest in the U.S.
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The University of Nebraska Medical Center (UNMC) Eppley Cancer Center received $10.1 million in total funding from the NCI for FY 2005, and has been an NCI-designated Cancer Center since 1983.

As part of an elite group of NCI-designated Cancer Centers, the mission of the University of Nebraska Medical Center (UNMC) Eppley Cancer Center is to coordinate basic research and clinical cancer research, patient care, and educational programs and to facilitate application of new knowledge about the etiology, diagnosis, treatment, and prevention of cancer and to improve health and quality of life.

- The UNMC Eppley Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- The UNMC Eppley Cancer Center is the only NCI-designated cancer center in Nebraska and in the central region of the U.S. from North Dakota to Texas
- The innovative Cancer Research Graduate Program (CRGP) is offered through the Eppley Institute to train future scientists to approach cancer research knowledgeably and creatively
- Currently participating in a Genome-Wide RNAi Global Initiative with 17 other leading cancer research institutions that are located across North America and Europe
- More than 75 active and open clinical trials available to patients at this facility
- Home to more than 100 world-renowned specialists in laboratory and clinical sciences
- In conjunction with its affiliated hospital (The Nebraska Medical Center), the UNMC Eppley Cancer Center treated over 2,300 new patients in 2006.
- UNMC staff educate the public on prevention and early detection by traveling across Nebraska, educating citizens and health care professionals, and participating in community-service events
- More than $40 million in total peer-reviewed funding
- The UNMC Eppley Cancer Center has an expression profiling project supported by the NCI Director's Challenge grant

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Since opening in 2005, the Nevada Cancer Institute has received $555,204 in total funding from NCI.

Nevada Cancer Institute (NVCI) is a team of dedicated professionals committed to advancing the frontiers of knowledge about cancer through research and providing world-class, research-based cancer services to Nevadans and people throughout the southwest. Our research-linked, comprehensive cancer facility opened late summer 2005 and is dedicated to state-of-the-art research and implementation of groundbreaking methods of prevention, detection and treatment of cancer. It treats patients on an outpatient basis.

- NVCI offers patients a number of clinical trials in advanced cancer, gastrointestinal, lung hematological, genitourinary and melanoma
- Employs 260 staff with 24 clinicians and researchers
- Participating in more than 50 Phase I/II clinical trials in advanced cancers including gastrointestinal, genitourinary, respiratory, hematological and melanoma
- More than 1,500 patients treated since opening late 2005
- Outreach and education services throughout Nevada with offices in three cities outside Las Vegas; Elko, Fallon and Sparks (Reno)
- NVCI hosts community events and cancer specific support groups
- Received the Worksite Wellness, Gold Award Wellness Coalition of America (WELCOA); the first ever awarded in Nevada
- Features a full electronic medical record system
- Patient Cares Fund, a program developed to help cancer patients with non-medical financial assistance

June 2008
NEW HAMPSHIRE

NORRIS COTTON CANCER CENTER
DARTMOUTH COLLEGE/DARTMOUTH-HITCHCOCK MEDICAL CENTER

Lebanon, New Hampshire (2nd Congressional District)
HTTP://WWW.CANCER.DARTMOUTH.EDU

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Norris Cotton Cancer Center received $25.7 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1978.

Norris Cotton Cancer Center combines advanced cancer research at Dartmouth Medical School with patient-centered cancer care at Dartmouth-Hitchcock Medical Center. One of an elite group of NCI-designated centers, the Cancer Center strives to develop new strategies to prevent, treat, and cure cancer and to provide effective and compassionate treatment and support for cancer patients and their families.

- The Norris Cotton Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only one in the state of New Hampshire
- The Norris Cotton Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2007
- Supported by more than $41 million in peer-reviewed research grants annually
- More than 230 active research projects foster interdisciplinary investigation into the biology, causes, prevention, and treatment of cancer
- Participates or leads more than 150 open clinical trials
- Serves more than 2,800 new patients each year and 20,000 patients annually
- Provides continuing education and consultation for physicians and cancer care professionals in the region
- Includes more than 130 principal investigators, 150 clinical cancer specialists, and 500 staff
- Bone Marrow Transplant Program offers autologous and allogeneic transplants in both the inpatient and outpatient setting
- Familial Cancer Program provides cancer genetics services including family history analysis, risk assessment, and genetic testing
- Cancer Survivorship and Palliative Care Program addresses the needs of patients and families across the continuum of care

June 2008
NEW JERSEY

THE CANCER INSTITUTE OF NEW JERSEY
ROBERT WOOD JOHNSON MEDICAL SCHOOL

New Brunswick, New Jersey (6th Congressional District)
HTTP://WWW.CINJ.ORG

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Cancer Institute of New Jersey (CINJ) received $20.1 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1997.

As part of an elite group of NCI-designated Cancer Centers, The Cancer Institute of New Jersey (CINJ) opened its doors with a commitment to learning more about cancer and making those discoveries available to the public to aid in disease prevention.

| CINJ is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only one in the state of New Jersey |
| CINJ is one of 63 cancer centers in the national network of NCI-designated Cancer Centers |
| More than 160 physicians and researchers and over 500 total employees |
| More than 1,000 patients were enrolled in clinical trials through CINJ in 2005 |
| Community-based partnerships to reduce the mortality rate in underserved populations |
| Houses centers for prostate cancer, breast cancer, women's reproductive cancers, and diet and nutrition |
| Network of 16 hospitals across New Jersey making it one of the largest networks in the nation |
| More than 75,000 patient visits in 2005 with almost 10 percent pediatric patients |
| The Levine Laboratory at CINJ discovered, and is a leading authority on the tumor suppressor gene called "p53," which is mutated and functionally inactivated in over half of all cancers |
| Holds monthly basic science and clinical lectures for medical professionals |
| Home of the Resource Learning Center, open to the public, providing a place where patients and their families can research and find information about cancer |

June 2008
NEW MEXICO

UNIVERSITY OF NEW MEXICO CANCER CENTER

Albuquerque, New Mexico (1st Congressional District)
HTTP://CANCER.UNM.EDU

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The University of New Mexico Cancer Center (UNM) received $10.8 million in total NCI funding for FY 2007, and has been an NCI-designated Cancer Center since 2005.

The University of New Mexico Cancer Center in Albuquerque is dedicated to studying the genetic, environmental and behavioral risk factors that contribute to striking differences in cancer patterns and outcomes among the southwest’s multi-ethnic population. In partnership with Sandia and Los Alamos National Laboratories, the center has highly integrated nanotechnology, engineering and physical sciences with its research programs.

- UNM is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2006
- Designated for 36 years as the official cancer center of the state. The center received special commendations from the legislature in 2003 and 2005.
- Served 6,500 patients in more than 80,000 clinic visits in 2006
- Conducted 178 clinical trials in 2006. Of the 1,964 new cancer patients treated in 2006, 12 percent were part of therapeutic trials – up from 6 percent in 2002
- Outreach clinics are open in Las Cruces, Santa Fe, and Farmington
- Students in the UNM Cancer Center graduate program have access to state-of-the-art facilities in microscopy, flow cytometry, genomics, nanoscience, and the analysis of gene expression
- Researchers helped develop a vaccine against HPV, a virus that causes cervical cancer
- Researchers are investigating a new estrogen receptor, which is changing the way breast cancer and other estrogen-related cancers are treated. And new gene discoveries have lead to better outcome predictions and treatment for children with acute lymphocytic leukemia
- Community outreach teams are identifying cancer health needs throughout the state, and working to reduce health disparities among racial ethnic minorities -- including 19 Pueblos and the Navajo Indian Nation -- through education and research

June 2008
NEW YORK

ALBERT EINSTEIN CANCER CENTER
YEHSIVA UNIVERSITY

Bronx, New York (7th Congressional District)
HTTP://WWW.AECOM.YU.EDU/CANCER

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Albert Einstein Cancer Center received $24.5 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1972.

The Albert Einstein Cancer Center (AECC) was one of the first NCI-Designated Cancer Centers following passage of the National Cancer Act of 1971. The mission of AECC is to bring together all the diverse strengths of the College of Medicine to focus on, and foster basic, clinical, population-based, and translational research that addresses all aspects of the cancer problem.

- Albert Einstein Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- There are currently 121 members of AECC who represent eight basic science and six clinical departments
- Seven established research programs: Immuno-oncology; Tumor Microenvironment and Metastasis; Cell Growth and Differentiation Control; Molecular Membrane Biology; Experimental Therapeutics; Cancer Epidemiology; Biology of Colon Cancer
- Serves approximately 3,250 new cancer patients each year
- Approximately 175 clinical trials open each year
- Clinical research activities of the Cancer Center are based primarily at the Montefiore Medical Center (MMC), the University Hospital of the Albert Einstein College of Medicine, comprised of two divisions with a total of 1100 beds
- The population served by MMC is 52% Hispanic and 32% African-American
- The Montefiore Children’s Hospital, completed in 2004, is the site of the new Pediatric Hematology-Oncology program
- Disease-specific translational, multidisciplinary activities in the areas of lung, head and neck, and breast cancer and osteosarcoma

June 2008
Cold Spring Harbor Laboratory (CSHL) is a private, non-profit research and educational institution that has long been recognized for excellence in the biological and biomedical sciences. Research programs at CSHL have led to the identification of new genes involved in cancer and the elucidation of the role these genes play in development and progression of the disease. While the Cold Spring Harbor Laboratory Cancer Center does not provide patient care, it does focus on innovative basic research with the goal of understanding the molecular processes that give rise to cancers and using sophisticated technologies to improve cancer diagnosis, identify better drug targets and ultimately improve cancer therapies.

- CSHL is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- CSHL is a basic laboratory center, and does not provide clinical services to patients
- 30 principal investigators and more than 200 scientists working in three Cancer Center Programs - Cancer Genetics & Bioinformatics, Signal Transduction, and Gene Regulation
- Scientists at CSHL have made significant contributions in the areas of fields of RNA interference, signal transduction, cancer gene discovery and development of cancer animal models
- Recent work has revealed several new cancer genes: the tumor suppressor CHD5; a microRNA cluster mir-17-92; Yap and cIAP1 in hepatocellular cancer; and an mRNA splicing factor, SF2/ASF. These discoveries were made possible by technologies developed at CSHL, including representational oligonucleotide microarray analysis (ROMA), RNAi libraries and novel cancer animal models
- Research efforts at CSHL include studies of leukemia and lymphoma, malignant melanoma, breast, ovarian, cervical, colon, lung, pancreatic, and brain cancer
- The CSHL’s DNA Learning Center provides general education on DNA, human diseases and cancer through courses and interactive websites
NEW YORK

HERBERT IRVING COMPREHENSIVE CANCER CENTER
COLUMBIA UNIVERSITY MEDICAL CENTER & NEW YORK-PRESBYTERIAN HOSPITAL

New York, New York (15th Congressional District)
HTTP://CANCERCENTER.COLUMBIA.EDU

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, typically at academic institutions, receive core grant funding from NCI (called P30 grants) and are hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many researchers within cancer centers receive NCI funding as independent investigators through a variety of NCI extramural research grant mechanisms.

The Herbert Irving Comprehensive Cancer Center received $25.8 million in total funding from the NCI for FY 2007 and has been an NCI-designated Cancer Center since 1972.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and the New York-Presbyterian Hospital is to eradicate cancer through research, education, and patient care.

- Herbert Irving Comprehensive Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- Herbert Irving Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2007
- Treats more than 3,000 new cancer patients annually from across the New York-New Jersey-Connecticut tri-state area, as well as from the Caribbean, other areas of the world and across the United States
- Approximately 240 active clinical trials open for enrollment each year
- More than 200 faculty members
- Holds NCI-funded training programs in cancer biology and epidemiology
- Part of the NIH Roadmap for Medical Research, the cancer center hosts a National Center for Multi-Scale Analysis of Genetic and Cellular Networks (MAGNet) to create computational methods and tools to help solve one of the biggest challenges in biology: understanding how genes and proteins inside cells work together to implement specific biological processes – most significantly, the initiation of cancer
- An NIH Clinical and Translational Science Award (CTSA) supports a new educational program to prepare young cancer researchers and clinicians for successful careers in translational research – quickly translating laboratory discoveries into patient care enhancements, and patient care discoveries into research targets in the lab

June 2008
NEW YORK

James P. Wilmot Cancer Center
University of Rochester Medical Center

Rochester, New York (28th Congressional District)
HTTP://WWW.STRONGHEALTH.COM/SERVICES/CANCER/

Under the National Cancer Act of 1971, our national cancer program
led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading
cancer centers across the country dedicated to eradicating cancer through comprehensive and
multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of
these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition,
researchers within the larger network of cancer centers nationwide receive NCI funding as independent
investigators through a variety of NCI extramural research mechanisms. These cancer centers are
internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education
for health care professionals and the public. Many current therapies and cures used today were first
investigated at these centers, and they actively partner with local community and state health agencies to
bring these discoveries to patients.

James P. Wilmot Cancer Center received $47 million in total funding from NCI in FY 2006.

The James P. Wilmot Cancer Center at the University of Rochester Medical Center is a state-of-the-art
clinical cancer center with a focus on providing outstanding care for people with cancer by offering the
latest and most effective therapies in a compassionate setting; conducting significant interdisciplinary
cancer-related research, from prevention to post-cancer quality-of-life issues; translating advances in the
basic sciences into meaningful cancer treatments; and providing superior education and training
programs for students and fellows in areas related to cancer research and clinical care.

- The Center has 500 faculty and staff working in radiation oncology, surgical oncology,
  hematology oncology, and pediatric oncology
- Thirty-year history of excellence in patient care, research, education, and community
  outreach in the state of New York
- The Center has the largest clinical program for lymphoma in the Northeast and has led
  the expansion of the use of stereotactic radiosurgery from the brain to other solid
  organs throughout the body
- With growing translational research programs in lung biology, immunology, genetics, cell
  biology, and DNA repair, the Center is committed to quickly bringing discoveries from the bench to the bedside
- The Center is the research base for the Community Clinical Oncology Program for
  multi-center cancer control studies
- The Center performs the most blood and marrow transplants in the state, outside of
  New York City. And its 100-day survival rates exceed national benchmarks
- The Center offers residency programs for radiation oncology and hematology/oncology
  and a fellowship program in hematology/oncology
- Key research programs focus on biomedical genetics and translational research for
  hematologic malignancies

June 2008
NEW YORK

MEMORIAL SLOAN-KETTERING CANCER CENTER

New York, New York (14th Congressional District)
HTTP://WWW.MSKCC.ORG

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Memorial Sloan-Kettering Cancer Center received $82.4 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1973.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Memorial Sloan-Kettering Cancer Center is to offer the best possible treatment for cancer today, to conduct research to discover more effective strategies to diagnose and treat cancer tomorrow, and to train future generations.

- Memorial Sloan-Kettering Cancer Center (MSKCC) is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation

- Memorial Sloan-Kettering Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers

- Ranked by US News & World Report as one of the top 10 cancer hospitals in the United States in 2007, and consistently ranked as one of the two top cancer hospitals in the United States

- Founded in 1884, MSKCC is the world’s oldest and largest private cancer center, and today has a staff of more than 9,300 and almost 900 volunteers

- In 2006, more than 21,000 patients were admitted, and the Center accommodated more than 430,000 outpatient physician visits

- MSKCC currently has more than 400 clinical trials for pediatric and adult cancers

- NCI support for research at MSKCC includes a SPORE grant for translational research in prostate cancer; a grant to develop a clinical proteomic technology center; and a grant to establish a Cancer Genome Characterization Center, which will be a key component of The Cancer Genome Atlas Pilot Project

- In 2003, MSKCC received a five-year award from the NCI and the NIA to accelerate and establish research addressing the relationship between aging and cancer

- MSKCC is one of the NCI’s 15 regional Cancer Information Service (CIS) offices and is a part of the CIS Partnership Program, which provides technical assistance to reach diverse communities and underserved audiences

- Named a LIVESTRONG Survivorship Center of Excellence by the Lance Armstrong Foundation

June 2008
NEW YORK UNIVERSITY CANCER INSTITUTE

New York, New York (14th Congressional District)
HTTP://WWW.NYUCI.ORG

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

New York University Cancer Institute received $42.6 million in total funding from the NCI for FY 2007 and has been an NCI-designated Cancer Center since 1975.

As part of an elite group of NCI-designated Cancer Centers, the mission of the New York University Cancer Institute (NYUCI) is to decrease and eliminate cancer as a significant health problem throughout New York, the nation, and the world, by developing and maintaining excellent programs in patient care, research, education, and prevention.

- NYUCI is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2006
- More than 150 oncology clinical trials available for patients
- Community Outreach and Education programs serve NYUCI’s diverse population, to increase access to and care for the medically underserved patients
- Research areas in immunology and immunotherapies, developmental cancer genetics, stem cell biology, molecular and cellular biology
- Offers specialty programs for individuals seeking screening, prevention, and possible intervention for cancer risk reduction available through the 100 Women in Hedge Funds National Ovarian Cancer Early Detection Program and the Screening and Prevention Programs funded by The Lynne Cohen Foundation for Ovarian Cancer Research
- The expansion of clinical and research space (13-level 85,000 sq ft Clinical Cancer Center and laboratory facilities totaling 31,500 sq ft) across NYUCI campus enables translational research/disease based programs to develop and bridge research and patient care

June 2008
NEW YORK

Roswell Park Cancer Institute
State University of New York
Buffalo, New York (28th Congressional District)
HTTP://WWW.ROSWELLPARK.ORG

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Roswell Park Cancer Institute received $36.0 million in total funding from the NCI for FY 2007 and has been an NCI-designated Cancer Center since 1974.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Roswell Park Cancer Institute is dedicated to providing total care to the cancer patient. Founded as America’s first cancer center in 1898, Roswell Park Cancer Institute is dedicated to conducting research into the causes, treatment, and prevention of cancer; and to educating the public and the next generation of those who study and treat cancer.

- Roswell Park Cancer Institute is one of only 39 NCI-designated comprehensive cancer centers in the nation
- Roswell Park Cancer Institute is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2006
- Employs more than 2,900 people, including 470 nurses, 135 physicians and 107 senior scientists
- One in four eligible patients are currently participating in clinical trials
- In 2006, more than 4,200 patients were admitted and the center accommodated 162,000 outpatient visits
- Recently performed 500th robotic surgical case since initiation of program in fall of 2004 - one of the largest and most successful in the Northeast
- Instituted the nation’s first chemotherapy program in 1904
- Pioneered gold-standard chemotherapy for colorectal cancer treatment
- Discovered the prostate specific antigen (PSA) test for prostate cancer
- Developed photodynamic therapy used for treatment of melanoma, esophageal and lung cancer through manufacturing and testing

June 2008
NEW YORK

STONY BROOK UNIVERSITY CANCER CENTER
STATE UNIVERSITY OF NEW YORK STONY BROOK

Stony Brook, New York (1st Congressional District)
HTTP://WWW.STONYBROOKHOSPITAL.COM/index.cfm?id=953

Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Stony Brook University Cancer Center received $8.93 million in total funding from NCI in FY 2005.

The Stony Brook University Cancer Center is dedicated to providing the best comprehensive care for today's cancer patient, while striving to understand the causes of cancer, in order to prevent the disease and to develop more effective methods for curing it. The Center is characterized by its ability to provide efficient, accurate diagnosis, evidence-based treatment, and the most current information together with counsel and physical and psychosocial support. Stony Brook University Cancer Center provides an integrated framework for care and promotes multidisciplinary and translational research.

- The Center is studying environmental links to incidence of breast and prostate cancer on Long Island
- Received the highest approval rating for a teaching hospital cancer program by the American College of Surgeon's Commission on Cancer
- Serves more than 200 patients annually
- Long Island's only comprehensive cancer program backed by University-based researchers
- Includes multidisciplinary health care teams who provide comprehensive care for breast, colon, prostate, lung, head and neck, and GI cancers, as well as for gynecological, neurological and pediatric cancers, leukemia, lymphoma, and melanoma and sarcoma
- Opened a new 65,000 square foot Center for Outpatient Services - The facility includes The Imaging Center, The Center for Pain Management, and the Outpatient Cancer Center, which includes the Carol M. Baldwin Breast Care Center, Medical Oncology, Pediatric Hematology/Oncology, and Surgical Oncology

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Duke Comprehensive Cancer Center received $55.6 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1973.

The Duke Comprehensive Cancer Center was established in 1973 by the National Cancer Institute (NCI) as one of the original eight comprehensive cancer centers. Duke patients represent virtually every county in North Carolina and every state in the nation. An additional 15,000 new cancer patients have access to services offered by the Duke Oncology Network, a collaborative effort by the Duke University Health System and the Duke Comprehensive Cancer Center. Through this effort, the Cancer Center affiliates with hospitals and private practices throughout North Carolina and the Southeast in order to provide patients with the highest quality of cancer care.

- Duke Comprehensive Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- Duke Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by *US News & World Report* as one of the top 10 cancer hospitals in the United States in 2007
- Last year, nearly 5,000 new patients were diagnosed and treated for cancer in over 150,000 clinic visits
- SPORE grants for brain and breast cancers
- Researchers at Duke led the development of Tykerb, a drug approved by the FDA in 2007 to treat advanced, metastatic breast cancer
- 17,500 active cancer patients worldwide who have been evaluated and treated at Duke since 1990 are followed by the Cancer Center’s Tumor Registry
- Duke scientists developed the first-ever genomic test to predict which patients with early-stage lung cancer will need chemotherapy to live and which patients can avoid the toxic regimen of drugs
- Researchers at the Duke Center for Nicotine and Smoking Cessation Research were the first to develop the nicotine patch
- Research to develop a blood test to detect ovarian cancer was conducted by a Duke researcher
- Approximately 400 open clinical trials

*June 2008*
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Lineberger Comprehensive Cancer Center at the University of North Carolina is to reduce cancer occurrence and death in North Carolina and the nation through research, treatment, training, and outreach.

- Lineberger Comprehensive Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- Lineberger Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2007
- Ranked in the top 15 institutions nationally in cancer research funding with substantial programs in basic, clinical, and population sciences
- Home to internationally recognized research programs, including SPORE grants for breast cancer and gastrointestinal cancer
- NIH funding led to one of the largest ever population-based case-control studies of breast cancer examining racial disparities
- UNC Lineberger has one of seven cancer nanotechnology grants (CCNEs) and one of eleven Cancer Genome Atlas Grants
- More than 100,000 patient visits in 2006 including about 2,600 new patients
- Using a multidisciplinary approach, UNC Lineberger's growth led to construction of a new North Carolina Cancer Hospital that will open in 2009
- Nationally recognized training programs for the next generation of medical professionals
- Home of the Carolina Community Network, a program that aims to reduce breast, prostate, and colorectal cancers in adult African-Americans
- Employs 1,000 staff along with the Center’s 270 members, drawn from more than 25 departments across the UNC campus

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Comprehensive Cancer Center of Wake Forest University is to provide excellent health care while advancing the clinical and academic missions of each affiliated institution.

- Comprehensive Cancer Center of Wake Forest University is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- Comprehensive Cancer Center of Wake Forest University is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Physicians were the first to treat a brain tumor with the FDA-approved GliaSite Radiation Therapy System
- One of the first centers in the nation to offer individualized radiation treatment
- Home SPOREs in Prostate Cancer, Brain Tumor, and Breast Cancer
- Thirteen cancer specialists named in “America’s Top Doctors for Cancer” in 2006
- Home of an Integrated Brachytherapy Unit – one of only five such units in North America – reducing overall treatment time for each patient
- Home to North Carolina’s first Gamma Knife, a non-invasive stereo tactic radio surgical tool used to treat benign and malignant brain tumors
- Provides Psychosocial Oncology and Cancer Patient Support to enhance the life of patients and family members during diagnosis, treatment, and survivorship
- Twenty affiliate hospitals and 87 satellite clinics provide services to patients from 91 North Carolina counties and 39 additional states

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, Case Comprehensive Cancer Center focuses on cancer research to develop clinical trials, cancer prevention, and control activities for residents of Northeast Ohio.

- Case Comprehensive Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- Case Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 25 cancer hospitals in the United States in 2007
- Received a five-year award in September 2003 from the NCI and the NIA to accelerate and establish research addressing the relationship between aging and cancer
- Case Western, the Ireland Cancer Center of University Hospitals, Case Medical Center, and the Cleveland Clinic are partner institutions in the Case Comprehensive Cancer Center
- Case has an extensive range of scientific programs including Cancer Genetics, Cell Proliferation and Cell Death, and Radiation and Cellular Stress Response
- Employs more than 300 scientists and physicians and more than 170 active cancer trials
- Case is currently developing a scientific program concerning cancer and aging
- Combines resources and expertise with its affiliated hospitals: University Hospitals, Case Medical Center, Cleveland Clinic Foundation, Veterans Affairs Medical Center, and MetroHealth Medical Center
- Dedicated to training the next generation of scientists in a variety of different fields within the Center

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Cleveland Clinic Taussig Cancer Center received $15.88 million in total funding from NCI in FY 2005.

The Cleveland Clinic Taussig Cancer Center is dedicated to providing compassionate health care of the highest quality in a setting of education and research. At the Taussig Cancer Center, patients and their families benefit from innovative, leading-edge cancer care resulting from numerous discoveries in the laboratory and many years of clinical cancer research experience.

- Ranked by *U.S. News & World Report* as one of the top 25 cancer hospitals in the United States in 2007
- Cleveland Clinic Taussig Cancer Center partnered with Case University and the Ireland Cancer Center of University Hospitals of Cleveland to create the Case Comprehensive Cancer Center, an NCI-designated comprehensive cancer center
- Serves more than 26,000 patients at main campus location for a total of more than 180,000 patient visits annually
- Nearly 300 physicians and scientists serving patients
- Multidisciplinary clinics, including those focused on geriatric oncology, psycho-oncology, late effects, bone metastases, and tumor specific clinics.
- Awarded $7.4 million five-year grant from NCI for Genome wide association study of colorectal cancer
- At any given time, the Taussig Cancer Center offers nearly 300 clinical trials for qualifying patients
- Home to the Scott Hamilton CARES Initiative, which pairs newly diagnosed patients with cancer survivor volunteers, sponsors a website for patients and families, provides research funding and hosts an annual ice show and gala
- The Experimental Therapeutics Program has been actively involved in clinical trials that have led to several important new drugs

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Ohio State Comprehensive Cancer Center received $39.0 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1974.

As part of an elite group of NCI-designated Cancer Centers, the mission of The Ohio State University Comprehensive Cancer Center (OSUCCC) incorporates basic research, clinical/translational research, and prevention research.

- The Ohio State Comprehensive Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- The Ohio State Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 15 cancer hospitals in the United States in 2007
- OSUCCC is a network of seven interdisciplinary programs
- Serving Ohio residents with 7,420 inpatient visits and almost 160,000 outpatient visits
- 160 licensed patient beds, including a 24-bed blood and marrow transplantation unit
- 26 basic research laboratories and support facilities
- Named a LIVESTRONG Survivorship Center of Excellence by the Lance Armstrong Foundation
- Affiliated with Columbus Children’s Hospital and Cincinnati Children’s Hospital Medical Center
- Private chemotherapy stations in a variety of locations, plus a pharmacy dedicated to chemotherapy
- A founding member of the National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers that defines and sets national standards for cancer care
- Home of “It’s All About Health,” a radio program focused on health issues affecting African-Americans in Ohio

June 2008
Ohio

UC Barrett Cancer Center at University Hospital
University of Cincinnati

Cincinnati, Ohio (1st Congressional District)

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled network of nearly 90 leading cancer centers across the country dedicated to eradicating cancer through a comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers have NCI designation and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

June 2008

University of Cincinnati College of Medicine received $11.55 million in total funding from NCI in FY 2005.

In August 2007, Cincinnati Children's Hospital Medical Center (CCHMC), the University of Cincinnati (UC) College of Medicine and Academic Health Center (AHC) and University Hospital (UH) made a five-year commitment to invest up to $60 million in a joint cancer program (JCP) to coordinate life-long oncology care and combine the scientific and intellectual resources necessary to produce internationally significant research. The JCP includes a leading clinical research center for pediatric cancer, with more than 200 research studies involving more than 1,000 children, and an active adult cancer clinical trials office with more than 123 studies open to enrollment or follow-up. The program is also home to:

- An inpatient bone marrow transplant unit at CCHMC, which has performed more than 1,000 bone marrow transplants since 1981
- A three dimensional, external-beam radiation (TomoTherapy) and Novalis systems at Precision Radiotherapy at University Pointe, and the Varian image-guided radiotherapy system at UH
- The Fanconi Anemia Comprehensive Care Center at Cincinnati Children's, which is dedicated to compassionate multidisciplinary care of children with this disease and other rare bone marrow failure syndromes
- The Tristate’s only high-risk breast cancer clinic to offer ductal lavage and an American College of Radiology-accredited breast imaging center.
- Cutting-edge clinical research initiatives include gene therapy for high-risk brain tumors, targeted virus therapy for neuroblastoma and solid tumors, and radiation targeted therapies for pediatric neuroblastoma, leukemia, and lymphoma
- Specialized adult cancer treatments, including chemoperfusion for appendicle cancer, targeted radiation therapy for early-stage lung cancers, and certain brain tumors, minimally invasive video-assisted thoracoscopic lung surgery, advanced laparoscopy for kidney cancer, and robotic prostatectomy.

June 2008
As part of an elite group of NCI-designated Cancer Centers, the Oregon Health Science University (OHSU) Cancer Institute seeks to develop innovative, less toxic and more effective strategies of cancer prevention, treatment, diagnosis, and control by applying new discoveries in cancer cell biology in molecular genetics. OHSU Cancer Institute's major goal is to reduce cancer mortality in the State of Oregon by utilizing physician primary care networks to ensure maximum utilization of prevention and early diagnostic interventions with emphasis on underserved populations.

- OHSU is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Explores four research programs: Cancer biology, Hematologic Malignancies, Solid tumors, and Cancer Prevention and Control
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2007
- Currently more than 200 clinical trials
- Confirmed colonoscopy is the standard of care screening tool for colon cancer
- Employs more than 150 clinical, basic science, and population researchers
- Major accomplishments include: Imatinib (GLEEVEC) effective in the treatment of chronic myelogenous leukemia without toxicity, Herstatin effective in HER2/neu positive tumor cells, Calcitriol in high doses enhances prostate chemotherapy, and Fanconi Anemia D2 gene is linked with Breast Cancer genes BRCA1 and 2
- Office of Multicultural Affairs committed to addressing the cancer burden in the region
- Opened new Center for Health and Healing Cancer Care Center with programs in prostate, breast, and adolescent and young adult oncology multidisciplinary clinics, with plans to add sarcoma, gastrointestinal, and thyroid programs in 2008

June 2008
Abramson Cancer Center

University of Pennsylvania

Philadelphia, Pennsylvania (1st Congressional District)

HTTP://WWW.PENNHEALTH.ORG/ABRAMSON

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Abramson Cancer Center received $67.8 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1973.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Abramson Cancer Center at the University of Pennsylvania is to create new knowledge through leading-edge research and to provide hope to those whose lives have been touched by cancer through patient care excellence in the prevention, diagnosis, and treatment of cancer.

• Abramson Cancer Center is one of only 39 NCI-designated comprehensive cancer centers in the nation

• Abramson Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers

• Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2007

• Oversees one of the largest clinical trials programs in the country, with more than 225 trials available at any one time

• Recognized leader in interdisciplinary cancer research, patient care, and education

• Employs more than 300 active cancer researchers and 299 physicians involved in cancer prevention, diagnosis, and treatment.

• Opening in 2008, the Center for Advanced Medicine will provide state-of-the-art outpatient cancer services, including the Roberts Proton Therapy Center, a first-of-its-kind proton therapy center for the treatment of cancer

• Established the region’s first Center for Research on Early Detection and Cure of Ovarian Cancer

• Named a LIVESTRONG Survivorship Center of Excellence by the Lance Armstrong Foundation

• Annually sees more than 50,000 outpatient visits, 24,000 chemotherapy treatments, more than 65,000 radiation treatments, and 3,400 inpatient admissions

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Fox Chase Cancer Center received $33.7 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1974.

As part of an elite group of NCI-designated Cancer Centers, the mission of Fox Chase Cancer Center is to reduce the burden of cancer. Fox Chase’s activities include basic, clinical and prevention research, detection and treatment of cancer; and community outreach programs.

- Fox Chase Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- Fox Chase Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 15 cancer hospitals in the United States in 2007
- Fox Chase is recognized as a world leader in ovarian cancer research and has a corresponding SPORE in ovarian cancer
- Dedicated in 2000, the first comprehensive program of its kind in the nation, the Research Institute for Cancer Prevention, offers prevention-related services for people with family histories of cancer or specific risks
- Serves 4,000 inpatient and 69,000 outpatient visits annually
- Research is conducted in more than 80 laboratories by a staff of more than 325 physicians and scientists who hold medical degrees, PhDs, or both
- About 170 clinical trials of new prevention, diagnostic, and treatment techniques at any one time, with almost 800 patients annually participating in treatment studies
- The Cancer Research Pavilion at Fox Chase includes new laboratories dedicated to prevention-oriented research
- Established network of 30 hospitals in Pennsylvania and New Jersey in an effort to raise the quality of cancer care in the community and increase the number of patients enrolled in clinical trials
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, the mission of Kimmel Cancer Center at Thomas Jefferson University is to increase the survival and quality of life of cancer patients by transferring laboratory discoveries into strategies to prevent, diagnose, monitor, and cure cancer.

- Kimmel Cancer Center at Jefferson is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Many of the Kimmel Cancer Center at Jefferson’s oncologists have been featured in "Best Doctors in America" and contribute to leading scientific journals such as Cancer and Cell
- The Kimmel Cancer Center at Jefferson is part of the Jefferson Cancer Network (JCN), an association of about 20 hospitals within the Philadelphia metropolitan area
- Home to 150 physicians and scientists and 101 post-doctoral fellows in 49 laboratories
- Home to the Science Outreach Program to encourage children to pursue science
- Conducts approximately 100 clinical trials each year
- Basic and clinical science research programs designated in Cellular Biology & Signaling, Molecular Biology & Genetics, Immunological Mechanisms in Cancer, Endocrine Mechanisms and Hormone Action in Cancer, Molecular Targets & Developmental Therapeutics and Gastrointestinal Cancer
- Various federal and non-federal-supported pre- and post-doctoral training programs available that focus on Molecular Genetics, Cancer Immunology, DNA Damage Response, Translational Cancer Research, Developmental Immunology and Biomolecular Signal Transduction

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

**Penn State Cancer Institute received $11.6 million in total funding from NCI in FY 2005.**

Penn State Cancer Institute (PSCI) is a unique partnership founded by Penn State Hershey Medical Center, The Pennsylvania State University, Lehigh Valley Hospital and Health Network, and Mount Nittany Medical Center. Along with its affiliate members (Lewistown Hospital, Wyoming Valley Health Care System, and Susquehanna Health System), Penn State Cancer Institute is dedicated to advancing cancer research through the discovery of new approaches to prevention and treatment; improving care delivery; enhancing survivorship and quality of life for people living with cancer; and educating health care professionals, patients, and caregivers in our communities.

- Treats more than 5,500 cancer patients per year
- Membership of 190 investigators in four scientific research programs: viral oncogenesis and host defense, experimental therapeutics, chemical carcinogenesis and chemoprevention, and cancer prevention and control
- Offers a range of treatment services and elective participation in more than 200 cancer research protocols
- Member of the Pennsylvania Cancer Alliance, a consortium of leading Pennsylvania cancer centers that promotes cancer research throughout Pennsylvania by using funds provided by a settlement between the Commonwealth of Pennsylvania and tobacco companies
- The Ronald McDonald House in Hershey offers a home away from home for the families of children with cancer and other serious illnesses
- The American Cancer Society’s Hope Lodge in Hershey provides low-cost lodging for adult patients and their families
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, the University of Pittsburgh Cancer Institute focuses on the development of early stage translational research aimed at rapidly translating scientific discoveries to benefit patient care.

- The University of Pittsburgh Cancer Institute is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation
- The University of Pittsburgh Cancer Institute is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by U.S. News & World Report as one of the top 15 cancer hospitals in the United States in 2007
- Received a five-year award in September 2003 from the NCI and the NIA to accelerate and establish research addressing the relationship between aging and cancer
- UPCI has SPOREs in head and neck cancers and lung cancer
- The only NCI Cancer Center in Western Pennsylvania, serving over 6 million residents with 36,000 cancer patients annually
- Employs 2,200, including 600 faculty and staff, representing more than 30 disciplines
- UPCI findings in clinical and basic research appear regularly in prominent publications such as New England Journal of Medicine, Journal of the American Medical Association, Journal of the National Cancer Institute, Science and Nature Medicine.
- Patients have access to approximately 160 open clinical trials
- The Center receives more than $120 million in federal grants, in addition to state funding and money from private donors and foundations
- Partnerships and collaborations with corporate partners in the region to bring the most promising care to residents in Western Pennsylvania

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, the Wistar Institute is a dedicated international leader in basic biomedical research and committed to training the next generation of scientists. The Wistar Institute does not provide direct patient care. Instead, Wistar scientists are focused on discovering the fundamental biological mechanisms underlying cancer with the aim of using that new knowledge to create advanced diagnostics and therapies for patients with cancer.

- Wistar Institute is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Wistar Institute is a basic laboratory center, and does not provide clinical services to patients
- Recently completed a $6.6 million five-year program project grant for research on metastatic melanoma
- Comprised of 33 laboratories, grouped into three research programs: Gene Expression and Regulation, Immunology, and Molecular and Cellular Oncogenesis
- Wistar Institute has a SPORE for skin cancer, one of only three in the nation
- The Institute led the identification of genes associated with breast, lung, prostate, and other forms of cancer
- 332 employees, including 67 postdoctoral trainees and 17 visiting scientists
- In the past decade, nearly 1,000 promising researchers, including predoctoral students, postdoctoral fellows, and visiting scientists, have trained at Wistar
- Researchers at this center have found that they can re-establish broken communication between cells, thus restoring control over cell division, a promising result that could point the way toward new melanoma therapies

June 2008
SOUTH CAROLINA

HOLLINGS CANCER CENTER
MEDICAL UNIVERSITY OF SOUTH CAROLINA
Charleston, South Carolina (1st Congressional District)
HTTP://HCC.MUSC.EDU/

Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Hollings Cancer Center received $12.1 million in total funding from NCI in FY 2007.

The Hollings Cancer Center is the largest academic-based cancer program in South Carolina. It has united the best medical, research, and scientific resources into a single location, with a singular focus on cancer. These resources are extended throughout the state via partnerships such as its ten institutional member Clinical Trials Network, ensuring that all residents have access to innovative care.

- Designated NCI Cancer Planning Center, submitting application May 2008
- Leads the coordination of state-wide efforts in research, education, and clinical care
- Currently building a new seven-story Hollings Cancer Expansion Facility
- Since 1992, the Center has been involved in hundreds of clinical trials
- The Translational Research Program explores areas for collaborative research on a variety of cancers
- Hollings Cancer Center is working on a Speakers Bureau of cancer specialists who can address topics of interest to the community

June 2008
TENNESSEE

ST. JUDE CHILDREN’S RESEARCH HOSPITAL

Memphis, Tennessee (9th Congressional District)
HTTP://WWW.STJUDE.ORG

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The St. Jude Children’s Research Hospital received $26.0 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1977.

As part of an elite group of NCI-designated Cancer Centers, the mission of St. Jude Children’s Research Hospital is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment.

- St. Jude Children’s Research Hospital is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Discoveries made at St. Jude have changed how the world treats children with cancer and other catastrophic diseases
- St. Jude is the only pediatric research center where no payment is expected for treatment beyond what is covered by insurance
- 4,700 patients are annually seen at St. Jude
- Employs more than 3,100 people
- Five affiliate hospitals in Tennessee, Alabama, Louisiana, and Illinois
- The hospital accepts children who have been treated elsewhere and are eligible for transplant, relapse, or Phase I or II clinical trial protocols
- Investigators at St. Jude discovered the role of several key genes in the development of the retina, and in the process have taken a significant step toward understanding how to prevent or cure the potentially deadly eye cancer, retinoblastoma

June 2008
TENNESSEE

VANDERBILT-INGRAM CANCER CENTER
VANDERBILT UNIVERSITY

Nashville, Tennessee (5th Congressional District)
HTTP://WWW.VICC.ORG

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Vanderbilt-Ingram Cancer Center received $65.2 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1995.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Vanderbilt-Ingram Cancer Center is the elimination of cancer in Tennessee, across the United States, and around the world.

- Vanderbilt-Ingram Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only one in state of Tennessee
- Vanderbilt-Ingram Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 25 cancer hospitals in the United States in 2007
- SPOREs in breast cancer, lung cancer, and gastrointestinal cancers
- 250 investigators in seven research programs and more than 200 active clinical trials in adults and children in Tennessee, Georgia, Florida, Kentucky and Virginia through the Affiliate Network
- More than $150 million in annual research funding
- Annually serves more than 3,800 new cancer patients and more than 57,000 outpatient visits
- Cancer Information Program providing information, via a toll free number, to over 3,000 people annually
- Awarded a Minority Partnership Grant with Meharry Medical College, with the goal of building research and clinical care opportunities, increasing the number of minorities who enter and are successful in cancer research and clinical care careers, and ultimately to reduce racial and ethnic disparities in cancer incidence and mortality
- Leads the Southern Community Cohort Study, along with Meharry Medical College, the largest population-based study ever to target African Americans and the Southeast

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

M.D. Anderson Cancer Center received $116.4 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1971.

The mission of M. D. Anderson Cancer Center is to eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

- One of 39 NCI-designated Comprehensive Cancer Centers, and the only one in Texas
- The University of Texas M.D. Anderson Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 10 cancer hospitals in the United States in 2007, and consistently ranked as one of the two top cancer hospitals in the United States.
- Has 10 SPOREs: breast, genitourinary, gynecologic, head and neck, leukemia, lung, ovarian, pancreatic, prostate and skin cancers
- Treats 79,500 patients annually, two-thirds of them Texas residents
- More than 11,000 patients participated in therapeutic clinical trials in 2006, the largest program in the nation
- Almost 4,400 students take part in health education programs annually
- Awards bachelor’s degrees in seven allied health disciplines and, in collaboration with The University of Texas Health Science Center at Houston, jointly confers master’s and Ph.D. degrees in biomedical sciences
- The first health care system in the U.S. to receive CEO Cancer Gold Standard accreditation for programs to promote workplace wellness for 16,000 employees
- 40,114 total jobs in the Houston region are supported by M. D. Anderson-generated activities, contributing to $2.9 billion in local and regional economic impact
- First Cancer Center to create a Department of Health Disparities Research to address broad issues affecting the unequal burden of cancer
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, the mission of the San Antonio Cancer Institute is to provide the organizational resources and framework required to promote interdisciplinary research in defined areas of basic science, clinical research, and cancer prevention and control. The San Antonio Cancer Institute is dedicated to fostering the application of the results of that research in the community setting, particularly in south Texas.

- The San Antonio Cancer Institute is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- A nationally known treatment center with nearly 100,000 patient visits annually
- Home of the Institute for Drug Development, a world-class anticancer drug development organization where many of the cancer therapies most recently approved by FDA underwent early testing
- Comprehensive Patient and Wellness Program offering psycho-social counseling, nutrition services, transportation and financial services, wellness, and support groups
- More than 180 ongoing cancer clinical trials are directed by this Center with the participation of four affiliate hospitals
- Employs more than 200 members of the scientific and research community
- Recently developed the Office of Cancer Survivorship, to include survivors and caregivers in the administration and operations of the facility
- Houses the Genetic Risk Assessment Clinic, providing individual risk assessment for hereditary cancer

The San Antonio Cancer Institute received $25.9 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1991.
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The Harold C. Simmons Comprehensive Cancer Center received $13 million in total funding from NCI in FY 2005.

The Harold C. Simmons Comprehensive Cancer Center at the University of Texas Southwestern Medical Center was established in 1989 through a generous gift from Dallas philanthropist Harold C. Simmons. It is a broad-based collection of cancer programs, each providing a wide range of patient care services. The team of physicians and their support staff are devoted to patients' health and well-being through the blending of leading edge cancer research with the best of conventional cancer care. The Simmons Comprehensive Cancer Center strives to be at the forefront of patient care by providing state-of-the-art diagnostic and therapeutic approaches that are specific to each patient's need. Below are examples of the unique research and patient care activities ongoing:

- Expert physicians in all cancer areas practicing as multidisciplinary teams
- A state-of-the-art radiation therapy facility with special emphasis on stereotatic radiosurgery
- Five distinct scientific cancer programs that build on a tradition of outstanding scientific discovery at UT Southwestern
- Research funded by a coveted Lung Specialized Programs of Research Excellence (SPORE) grant from the NIH, led by John Minna, M.D.
- 2,955 new cancer patients seen in 2006 by Simmons Cancer Center physicians
- Participation in more than 200 clinical trials
- UT Southwestern fellowship programs in hematology/oncology, gynecologic oncology and breast surgery, as well as a residency program in radiation oncology
- A specialized cancer biology training track in the UT Southwestern Graduate School of Biomedical Sciences
- Community outreach efforts to the medically underserved in Dallas through Parkland Hospital & Health System, as well as in Ft. Worth through Moncrief Cancer Resources

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Dan L. Duncan Cancer Center received $33.8 million in total funding from NCI in FY 2007.

The Dan L. Duncan Cancer Center is a consortium of Baylor College of Medicine, Texas Children's Hospital, Ben Taub General Hospital, and the Michael E. DeBakey Veterans Affairs Medical Center. Patient care is delivered at the five hospital partner sites. The goal of the Center is to provide a structure within this consortium for integrated multidisciplinary patient care, collaborative basic, translational and clinical research, and community education and outreach in order to reduce cancer incidence and mortality.

- Dan L. Duncan Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- The Center has SPOREs in breast cancer, prostate cancer, and lymphoma
- The Center has applied for a brain tumor SPORE
- Houses an internationally recognized pediatric oncology program with over 70 investigators, over 150 clinical trials and an array of specially awarded grants from NCI and NIH

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The University of Texas Medical Branch Comprehensive Cancer Center received $8.2 million in total funding from NCI in FY 2007.

The University of Texas Medical Branch (UTMB) Cancer Center was established in 2005, through the merging of the Sealy Center for Cancer Cell Biology, the Educational Cancer Center and the clinical enterprise. Today, the UTMB Cancer Center is a comprehensive organization encompassing clinical care, research, education and prevention in an effort to deliver advanced, high quality and compassionate care and services to its patients and communities. As a snapshot, the UTMB Cancer Center:

- Includes more than 125 members involved in patient care, research education and prevention
- Specializes in GI, liver and pancreas, breast, head and neck, prostate and lung cancers
- Serves more than 1,300 new cancer patients each year
- Conducts more than 16,000 outreach screenings for breast, cervical and skin cancers
- Receives more than $20 million per year in cancer-related research funding
- Directs a state-wide program in oncology for all Texas medical students; now a national model of excellence
- Involved in approximately 60 oncology clinical trials in 2008
- Features a Breast Imaging Center designated as a Center of Excellence by the American College of Radiology
- Offers liver and other major organ transplants through its Texas Transplant Center
- Directs an innovative mentorship program to assist and support junior investigators in cancer research reach their defined goals
- Enjoys strong community partnerships with the American Cancer Society, Susan G. Komen Foundation, Cancer Stop and others involved in cancer care and a search for a cure.

June 2008
Huntsman Cancer Institute
Salt Lake City, Utah (2nd Congressional District)
HTTP://WWW.HCI.UTAH.EDU

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

Huntsman Cancer Institute received $16.5 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1986.

As part of an elite group of NCI-designated Cancer Centers, the mission of Huntsman Cancer Institute (HCI) at the University of Utah is to understand cancer from its beginnings, to use that knowledge in the creation and improvement of cancer treatments, to relieve the suffering of cancer patients, and to provide education about cancer risk, prevention, and care.

- Huntsman Cancer Institute is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2007
- A leader in the study of human genetics, housing the Utah Population Database, the largest genetic database in the world
- A founding member of the National Comprehensive Cancer Network (NCCN), an alliance of the nation’s leading cancer centers that defines and sets standards for cancer care
- Houses the Huntsman Cancer Learning Center, which holds one of the nation’s largest collections of cancer-related publications for patient and public education. The CLC has served more than 56,000 visitors since 1999
- Conducts more than 100 clinical trials at any given time
- Recorded 10,685 outpatient clinic visits and more than 3,000 surgical cases in FY2006
- Employs more than 1,500 people, including research, clinical, and administrative staff
- Offers seminars and presentations to the public through the Cancer Education Outreach program, which has reached more than 40,000 people since 1999
- Offers high risk clinics for people at increased risk of developing breast, colon, and pancreas cancers and melanoma
- Supports a Special Populations program that works to overcome the barriers Native Americans and other medically underserved populations face in regard to cancer screening and care

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Vermont Cancer Center received $6.3 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1978.

As part of an elite group of NCI-designated Cancer Centers, the Vermont Cancer Center at the University of Vermont in collaboration with Fletcher Allen Health Care is dedicated to improving the human condition as it is affected by cancer, through fostering and sustaining: innovative research in the laboratory and in the clinic; cancer prevention and control research and programs; state-of-the-art cancer diagnosis and treatment; compassionate care that respects the individual patient; and education and community outreach.

- The Vermont Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only one in the state of Vermont
- The Vermont Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Focal point for cancer-related activities for Vermont and northern New York
- More than 100 researchers and physicians in addition to 30 staff committed to the fight against cancer
- Focus on both laboratory and population-based research
- Administers a number of national and regional clinical trials for both adults and children
- Provides support groups and support services to patients and their families

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Massey Cancer Center received $13.6 million in total funding from the NCI for FY 2007 and has been an NCI-designated Cancer Center since 1974.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Massey Cancer Center at Virginia Commonwealth University is to serve the commonwealth of Virginia and the nation as an internationally recognized institute of clinical, educational, and research excellence dedicated to improving the quality of human life through the prevention, control, and cure of cancer.

- Massey Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- 175 researchers and physicians from 28 VCU departments are turning research into new and improved treatments
- The patient population in the Central Virginia service area of the Cancer Center is approximately 40 percent minorities
- During the previous year, there were more than 100,000 outpatient visits and more than 2,400 inpatient admissions for patients with a diagnosis of cancer.
- Patients have access to more than 100 clinical trials
- New initiatives include a Cancer Survivors Clinic and a Cancer Survivors Symposium Series
- The Rural Cancer Outreach Program (RCOP) enables patients and their families to stay close to home while receiving state-of-the-art treatment from oncology experts
- Home to the award winning Thomas Palliative Care Unit, with a goal of enhancing the life of patients and family members during diagnosis, treatment, and survivorship
- A national leader in palliative care, education, and research
- The only comprehensive bone marrow transplant program in Virginia with more than 110 transplants in the most recent year
- Administers NCI-funded research training programs in cancer biology, cancer prevention and control, and radiation oncology translational research

June 2008
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators and cancer care providers. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

As part of an elite group of NCI-designated Cancer Centers, the mission of the University of Virginia (UVA) Cancer Center is to educate patients and the community on cancer prevention and the importance of early detection while providing compassionate and innovative care with a high regard for quality of life, support, and comfort. UVA Cancer Center is on the forefront of translational research - a blending of basic and clinical research that speeds more effective treatments to the bedside.

- UVA Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Twenty University of Virginia physicians were named to the 2006 list of America's Top Doctors for Cancer
- Ranked by US News & World Report as one of the top 50 cancer hospitals in the United States in 2007
- Over 200 investigators from 13 departments contribute to the research being conducted at this center
- Patients have access to more than 100 clinical trials
- Substantial contributor to the understanding of cancer cell and molecular biology
- Researchers at the UVA Cancer Center have devised an algorithm to match drugs quickly to tumor types, to speed up treatment and the drug discovery process
- Home of a Predoctoral Cancer Training Program, training graduate students with an emphasis in cancer-related research
- Patients and families receive robust support services that include genetics, palliative care, nutrition, spiritual care, educational resources, counseling and psychotherapy, support groups, massage, rehabilitation, financial and transportation services and music therapy

June 2008
WASHINGTON

FRED HUTCHINSON CANCER RESEARCH CENTER

Seattle, Washington (7th Congressional District)
HTTP://WWW.FHCRC.ORG

Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The Fred Hutchinson Cancer Research Center received $124.1 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1976.

As part of an elite group of NCI-designated Cancer Centers, the mission of the Fred Hutchinson Cancer Research Center is to eliminate cancer as a cause of human suffering and death.

- The Fred Hutchinson Cancer Research Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only one in the state of Washington
- The Fred Hutchinson Cancer Research Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Received a five-year award in September 2003 from the NCI and the NIA to accelerate and establish research addressing the relationship between aging and cancer
- Named a LIVESTRONG Survivorship Center of Excellence by the Lance Armstrong Foundation
- Played a leading role in the groundbreaking Women's Health Initiative study that revealed that hormone-replacement therapy can increase a woman’s risk of breast cancer, stroke, and heart disease
- The Fred Hutchinson Cancer Research Center leads two SPOREs in ovarian and prostate cancers
- Home to the largest bone marrow transplant program in the world
- Employs more than 2,600 scientists and staff, including three Nobel Laureates
- Home to the discovery of a promising treatment for patients with advanced melanoma
- Established a formal consortium in 2002 with the University of Washington which integrates the cancer research activities at Fred Hutchinson, University of Washington, and the Children's Hospital and Regional Medical Center, thus linking the effort of almost 400 cancer scientists and clinicians
- Home to the discovery that led to Mylotarg, the first FDA-approved, antibody-targeted chemotherapy that is a less toxic and more effective form of cancer treatment
- A discovery made collaboratively with Hutchinson Center researchers may allow for more accurate early detection of ovarian cancer

June 2008
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

Mary Babb Randolph Cancer Center (MBRCC) received $1.07 million in total funding from NCI in FY 2005.

The Mary Babb Randolph Cancer Center (MBRCC) is West Virginia’s most comprehensive cancer treatment, research, and education facility. The Center offers a multidisciplinary team approach and state-of-the-art technologies and treatments, as well as the latest clinical trials, and a variety of education and prevention outreach programs.

- Houses NCI’s Mid-Atlantic Cancer Information Service, the Betty Puskar Breast Care Center, and the Blood and Marrow/Transplant Hematologic Malignancy Program
- Recognized by the American College of Surgeons Commission on Cancer for providing the best in cancer care
- Presently organized into basic science programs (Tumor Microenvironment and Cell Signaling); clinical programs (Breast and Lung Cancer); and Population Health Research and Prevention
- The MBRCC leads several federally-funded programs designed to translate research findings into education programs and training for health care professionals and the public
- Funding from the National Center for Research Resource helped establish a Center of Biomedical Research Excellence in the area of cancer research which has led to exciting and innovative research
- $10.5M total direct funding in FY 2007
Under the National Cancer Act of 1971, our national cancer program led by the National Cancer Institute (NCI) created an unparalleled network of now nearly 90 leading cancer centers across the country dedicated to eradicating cancer through comprehensive and multidisciplinary program of cancer research in prevention, early detection, and treatment. Two-thirds of these centers are NCI-designated cancer centers and receive core grant funding from NCI. In addition, researchers within the larger network of cancer centers nationwide receive NCI funding as independent investigators through a variety of NCI extramural research mechanisms. These cancer centers are internationally known hubs of cutting-edge research, high quality cancer care, and outreach and education for health care professionals and the public. Many current therapies and cures used today were first investigated at these centers, and they actively partner with local community and state health agencies to bring these discoveries to patients.

The Medical College of Wisconsin Cancer Center received approximately $7 million in total funding from the NCI for FY 2006.

The Medical College of Wisconsin (MCW) Cancer Center is devoted to translating research into patient care. The MCW Cancer Center is the only academic cancer center located in Wisconsin's most populous region, encompassing more than 2.3 million people. It is a matrix cancer center with clinical facilities at Froedtert Hospital, Children’s Hospital of Wisconsin, and Zablocki VA Medical Center. More than 200 physicians and scientists are affiliated with the MCW Cancer Center.

- MCW scientists reported breakthroughs in functional magnetic resonance imaging, photodynamic therapy, low-dose radiotherapy, use of radio-protective agents, improved melanoma detection in sentinel lymph nodes, T cell-depleted bone marrow transplantation from unrelated donors, and breast cancer diagnosis and treatment
- Clinician-scientists in the Midwest Children’s Cancer Center at MCW pioneered now-standard procedures used to treat leukemia and other pediatric cancers
- Home to the Center for International Blood and Marrow Transplant Research, an NCI-funded database with records on more than 200,000 procedures done at 500 medical centers in 50 countries that has improved BMT outcomes internationally
- Recognized as an international model for palliative care physician training programs by the World Health Organization
- Approximately 150 active clinical trials at any given time, and nearly 125,000 outpatient visits in 2006
- The new Froedtert and MCW Clinical Cancer Center (opening May 2008) brings patient-centered site-based cancer clinics to Eastern Wisconsin for the first time
Under the National Cancer Act of 1971, the National Cancer Institute (NCI) created an unparalleled national network of NCI-designated Cancer Centers, now 63 centers strong. These cancer centers, often within academic institutions, are hubs of cutting-edge research, high quality cancer care, and training for our next generation of investigators. NCI also established the Specialized Programs of Research Excellence (SPORE) program, an effective research structure that empowers cancer centers to bring together top scientists from multidisciplinary fields to address specific cancer questions and bring new scientific knowledge from the laboratory to the bedside. NCI devotes more than 60 percent of its extramural research pool to supporting investigators in cancer centers across the country.

The University of Wisconsin Paul P. Carbone Comprehensive Cancer Center received $35.6 million in total funding from the NCI for FY 2007, and has been an NCI-designated Cancer Center since 1973.

As part of an elite group of NCI-designated Cancer Centers, the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center is dedicated to translating discoveries from research laboratories into new treatments that benefit cancer patients.

- The University of Wisconsin Paul P. Carbone Comprehensive Cancer Center is one of only 39 NCI-designated Comprehensive Cancer Centers in the nation, and the only one in the state of Wisconsin
- The University of Wisconsin Paul P. Carbone Comprehensive Cancer Center is one of 63 cancer centers in the national network of NCI-designated Cancer Centers
- Ranked by US News & World Report as one of the top 25 cancer hospitals in the United States in 2007
- Received a five-year award in September 2003 from the NCI and the NIA to accelerate and establish research addressing the relationship between aging and cancer
- More than 250 faculty members from 51 departments and nine schools
- More than 200 clinical trials each year
- Regional affiliations with 7 community cancer centers and offers medical oncology outreach to 6 clinics in Wisconsin
- Developed Tamoxifen, one of the best therapies for treating and preventing breast cancer
- Sponsored the nation’s first telephone-based cancer helpline, which has now become NCI’s Cancer Information Service hotline
- Led the first clinical trials with DFMO, a potential cancer-preventing agent
- One of three centers to participate in the national endostatin phase I clinical trial
- Serves 2.5 million people in southern and central Wisconsin and areas of Illinois

June 2008